William G. Wierda, M.D., Ph.D.

Peer-Reviewed Articles

1. Aslan B, Manyam G, Iles LR, Tantawy SI, Desikan SP, Wierda WG, Gandhi V. Transcriptomic and proteomic differences in BTK-WT and BTK-mutated CLL and their changes during therapy with pirtobrutinib. Blood Adv. e-Pub 2024. PMID: 38968154.
2. Wierda WG, Shah NN, Cheah CY, Lewis D, Hoffmann MS, Coombs CC, Lamanna N, Ma S, Jagadeesh D, Munir T, Wang Y, Eyre TA, Rhodes JM, McKinney M, Lech-Maranda E, Tam CS, Jurczak W, Izutsu K, Alencar AJ, Patel MR, Seymour JF, Woyach JA, Thompson PA, Abada PB, Ho C, McNeely SC, Marella N, Nguyen B, Wang C, Ruppert AS, Nair B, Liu H, Tsai DE, Roeker LE, Ghia P. Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study. Lancet Haematol. e-Pub 2024. PMID: 39033770.
3. Jain N, Wierda WG, O'Brien S. Chronic lymphocytic leukaemia. Lancet. e-Pub 2024. PMID: 39068951.
4. Kittai AS, Bond D, Huang Y, Bhat SA, Blyth E, Byrd JC, Chavez JC, Davids MS, Dela Cruz JP, Dowling MR, Duffy C, Ho C, Jacobson C, Jaglowski S, Jain N, Lin KH, Miller C, McCarthy C, Omer Z, Parry E, Rai M, Rogers KA, Saha A, Schachter L, Scott H, Senapati J, Shadman M, Siddiqi T, Stephens DM, Vanguru V, Wierda W, Woyach JA, Thompson PA. Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study. J Clin Oncol 42(17):JCO2400033, 2024. e-Pub 2024. PMID: 38552193.
5. Marvin-Peek J, Jen WY, Kantarjian HM, McCue D, Haddad FG, Wierda W, Ferrajoli A, Burger J, Abusab T, Jorgensen J, Wang SA, Patel K, Loghavi S, O'Brien S, Ravandi F. Long-term results of the sequential combination of cladribine and rituximab in Hairy cell leukemia. Leuk Lymphoma:1-10. e-Pub 2024. PMID: 38749022.
6. Wierda WG, Brown J, Abramson JS, Awan F, Bilgrami SF, Bociek G, Brander D, Cortese M, Cripe L, Davis RS, Eradat H, Fakhri B, Fletcher CD, Gaballa S, Hamid MS, Hill B, Kaesberg P, Kahl B, Kamdar M, Kipps TJ, Ma S, Mosse C, Nakhoda S, Parikh S, Schorr A, Schuster S, Seshadri M, Siddiqi T, Stephens DM, Thompson M, Ujjani C, Valdez R, Wagner-Johnston N, Woyach JA, Sundar H, Dwyer M. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024. J Natl Compr Canc Netw 22(3):175-204, 2024. PMID: 38626800.
7. Stilgenbauer S, Tausch E, Roberts AW, Davids MS, Eichhorst B, Hallek M, Hillmen P, Schneider C, Schetelig J, Böttcher S, Kater AP, Jiang Y, Boyer M, Popovic R, Ghanim MT, Moran M, Sinai WJ, Wang X, Mukherjee N, Chyla B, Wierda WG, Seymour JF. Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia. Blood Adv 8(8):1992-2004, 2024. PMID: 38290108.
8. Hampel PJ, Swaminathan M, Rogers KA, Parry EM, Burger JA, Davids MS, Ding W, Ferrajoli A, Hyak JM, Jain N, Kenderian SS, Wang Y, Wierda WG, Woyach JA, Parikh SA, Thompson PA. A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia. Blood Adv. e-Pub 2024. PMID: 38537065.
9. Liu P, Wang K, Li J, Ogasawara MA, Xia Z, Wierda WG, Keating MJ, Li Y, Huang P. Global miRNA profiling reveals key molecules that contribute to different chronic lymphocytic leukemia incidences in Asian and Western populations. Haematologica 109(2):479-492, 2024. e-Pub 2024. PMID: 37646669.
10. Short NJ, Jabbour E, Jain N, Senapati J, Nasr L, Haddad FG, Li Z, Hsiao YC, Yang JJ, Pemmaraju N, Ohanian M, Wierda WG, Montalban-Bravo G, Borthakur G, Han L, Xiao L, Huang X, Abramova R, Zhao M, Garris R, Konopleva M, Ravandi F, Kantarjian H. A Phase 1/2 Study of Mini-Hyper-CVD plus Venetoclax in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. Blood Adv 8(4):909-915, 2024. e-Pub 2024. PMID: 38207208.
11. Wierda WG. The approval of lisocabtagene maraleucel in chronic lymphocytic leukemia. Clin Adv Hematol Oncol 22(6):291-293, 2024. PMID: 39110651.
12. Sasaki K, Morita K, Kantarjian H, Garcia-Manero G, Jabbour E, Ravandi F, Konopleva M, Borthakur G, Wierda W, Daver N, Takahashi K, DiNardo C, Bravo GM, Issa GC, Pierce SA, Soltysiak KA, Tingen MS, Cortes JE. Geographic Disparity of Outcome in Patients with Cancer over Decades: The Surveillance, Epidemiology, and End Results. Clin Lymphoma Myeloma Leuk 23(11):e369-e378, 2023. e-Pub 2023. PMID: 37690903.
13. Thompson PA, Bazinet A, Wierda WG, Tam CS, O'Brien SM, Saha S, Peterson CB, Plunkett W, Keating MJ. Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up. Blood 142(21):1784-1788, 2023. PMID: 37595283.
14. Parry EM, Lemvigh CK, Deng S, Dangle N, Ruthen N, Knisbacher BA, Broséus J, Hergalant S, Guièze R, Li S, Zhang W, Johnson C, Long JM, Yin S, Werner L, Anandappa A, Purroy N, Gohil S, Oliveira G, Bachireddy P, Shukla SA, Huang T, Khoury JD, Thakral B, Dickinson M, Tam C, Livak KJ, Getz G, Neuberg D, Feugier P, Kharchenko P, Wierda W, Olsen LR, Jain N, Wu CJ. ZNF683 marks a CD8+ T cell population associated with anti-tumor immunity following anti-PD-1 therapy for Richter syndrome. Cancer Cell 41(10):1803-1816.e8, 2023. e-Pub 2023. PMID: 37738974.
15. Roccograndi LM, Lovell AR, Ferrajoli A, Thompson PA, Burger JA, Wierda WG, Jain N, Rausch CR. Incidence of major bleeding in patients with chronic lymphocytic leukemia receiving ibrutinib and therapeutic anticoagulation. Leuk Lymphoma 64(9):1-8, 2023. e-Pub 2023. PMID: 37317991.
16. Chiu CY, Ahmed S, Thomas SK, Wang LS, Mustafayev K, Fayad LE, Wierda WG, Khawaja F, Torres HA. Hepatitis B Virus Reactivation in Patients Receiving Bruton Tyrosine Kinase Inhibitors. Clin Lymphoma Myeloma Leuk 23(8):610-615, 2023. e-Pub 2023. PMID: 37150651.
17. Siddiqi T, Maloney DG, Kenderian SS, Brander DM, Dorritie K, Soumerai J, Riedell PA, Shah NN, Nath R, Fakhri B, Stephens DM, Ma S, Feldman T, Solomon SR, Schuster SJ, Perna SK, Tuazon SA, Ou SS, Papp E, Peiser L, Chen Y, Wierda WG. Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study. Lancet 402(10402):641-654, 2023. e-Pub 2023. PMID: 37295445.
18. Shah BD, Cassaday RD, Park JH, Houot R, Oluwole OO, Logan AC, Boissel N, Leguay T, Bishop MR, Topp MS, Tzachanis D, O'Dwyer KM, Arellano ML, Lin Y, Baer MR, Schiller GJ, Subklewe M, Abedi M, Minnema MC, Wierda WG, DeAngelo DJ, Stiff PJ, Jeyakumar D, Mao D, Adhikary S, Zhou L, Schuberth PC, Damico Khalid R, Ghobadia A. Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3. J Immunother Cancer 11(8), 2023. PMID: 37648261.
19. Bazinet A, Kadia T, Short NJ, Borthakur G, Wang SA, Wang W, Loghavi S, Jorgensen J, Patel K, DiNardo C, Daver N, Alvarado Y, Haddad FG, Pierce S, Nogueras Gonzalez G, Maiti A, Sasaki K, Yilmaz M, Thompson P, Wierda W, Garcia-Manero G, Andreeff M, Jabbour E, Konopleva M, Huang X, Kantarjian H, Ravandi F. Undetectable Measurable Residual Disease is Associated with Improved Outcomes in AML Irrespective of Treatment Intensity. Blood Adv 7(13):3284-3296, 2023. e-Pub 2023. PMID: 36884300.
20. Gordon MJ, Jones JE, George B, Peterson C, Burger JA, Jain N, Keating M, Wierda WG, Durand JB, Ferrajoli A. Long-term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: Focus on hypertension and cardiovascular toxicity. Cancer 129(14):2192-2200, 2023. e-Pub 2023. PMID: 37016930.
21. Allan JN, Flinn IW, Siddiqi T, Ghia P, Tam CS, Kipps TJ, Barr PM, Elinder Camburn A, Tedeschi A, Badoux XC, Jacobs R, Kuss BJ, Trentin L, Zhou C, Szoke A, Abbazio C, Wierda WG. Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia. Clin Cancer Res 29(14):OF1-OF9, 2023. e-Pub 2023. PMID: 37282671.
22. El Hussein S, Medeiros LJ, Gruschkus SK, Wei P, Schlette E, Fang H, Jelloul FZ, Wang W, Fiskus W, Kanagal-Shamanna R, Loghavi S, Yang H, Li S, Xu J, Tang Z, Thakral B, Jain N, Wierda WG, Patel K, Bhalla KN, Khoury JD. Immune evasion phenotype is common in Richter transformation diffuse large B-cell lymphoma variant. Virchows Arch 482(6):1011-1019, 2023. e-Pub 2023. PMID: 36864257.
23. Jabbour E, Short NJ, Senapati J, Jain N, Huang X, Daver N, DiNardo CD, Pemmaraju N, Wierda W, Garcia-Manero G, Montalban Bravo G, Sasaki K, Kadia TM, Khoury J, Wang SA, Haddad FG, Jacob J, Garris R, Ravandi F, Kantarjian HM. Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial. Lancet Haematol 10(6):e433-e444, 2023. e-Pub 2023. PMID: 37187201.
24. El Hussein S, Medeiros LJ, Lyapichev KA, Fang H, Jelloul FZ, Fiskus W, Chen J, Wei P, Schlette E, Xu J, Li S, Kanagal-Shamanna R, Yang H, Tang Z, Thakral B, Loghavi S, Jain N, Thompson PA, Ferrajoli A, Wierda WG, Jabbour E, Patel KP, Dabaja BS, Bhalla KN, Khoury JD. Immunophenotypic and genomic landscape of Richter transformation diffuse large B-cell lymphoma. Pathology 55(4):514-524, 2023. e-Pub 2023. PMID: 36933995.
25. Thompson PA, Keating MJ, Ferrajoli A, Jain N, Peterson CB, Garg N, Wang SA, Jorgensen JL, Kadia TM, Bose P, Pemmaraju N, Short NJ, Wierda WG. Venetoclax consolidation in high-risk CLL treated with ibrutinib for =1 year achieves a high rate of undetectable MRD. Leukemia. e-Pub 2023. PMID: 37138019.
26. Jain N, Senapati J, Thakral B, Ferrajoli A, Thompson P, Burger J, Basu S, Kadia T, Daver N, Borthakur G, Konopleva M, Pemmaraju N, Parry E, Wu CJ, Khoury J, Bueso-Ramos C, Garg N, Wang X, Lopez W, Ayala A, O'Brien S, Kantarjian H, Keating M, Allison J, Sharma P, Wierda W. A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL. Blood Adv 7(10):1958-1966, 2023. PMID: 36287248.
27. Kantarjian H, Short NJ, Jain N, Sasaki K, Huang X, Haddad FG, Khouri I, DiNardo CD, Pemmaraju N, Wierda W, Garcia-Manero G, Kebriaei P, Garris R, Loghavi S, Jorgensen J, Kwari M, O'Brien S, Ravandi F, Jabbour E. Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results. Am J Hematol 98(3):493-501, 2023. e-Pub 2023. PMID: 36600670.
28. Hoff FW, Griffen TL, Brown BD, Horton TM, Burger J, Wierda W, Hubner SE, Qiu Y, Kornblau SM. Reverse Phase Protein Array Profiling Identifies Recurrent Protein Expression Patterns of DNA Damage-Related Proteins across Acute and Chronic Leukemia: Samples from Adults and the Children's Oncology Group. Int J Mol Sci 24(6), 2023. e-Pub 2023. PMID: 36982537.
29. Griffen TL, Hoff FW, Qiu Y, Burger J, Wierda W, Kornblau SM. Prognostication of DNA Damage Response Protein Expression Patterns in Chronic Lymphocytic Leukemia. Int J Mol Sci 24(6), 2023. e-Pub 2023. PMID: 36982555.
30. Parry EM, Leshchiner I, Guièze R, Johnson C, Tausch E, Parikh SA, Lemvigh C, Broséus J, Hergalant S, Messer C, Utro F, Levovitz C, Rhrissorrakrai K, Li L, Rosebrock D, Yin S, Deng S, Slowik K, Jacobs R, Huang T, Li S, Fell G, Redd R, Lin Z, Knisbacher BA, Livitz D, Schneider C, Ruthen N, Elagina L, Taylor-Weiner A, Persaud B, Martinez A, Fernandes SM, Purroy N, Anandappa AJ, Ma J, Hess J, Rassenti LZ, Kipps TJ, Jain N, Wierda W, Cymbalista F, Feugier P, Kay NE, Livak KJ, Danysh BP, Stewart C, Neuberg D, Davids MS, Brown JR, Parida L, Stilgenbauer S, Getz G, Wu CJ. Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome. Nat Med 29(1):158-169, 2023. e-Pub 2023. PMID: 36624313.
31. Tantawy SI, Sarkar A, Hubner S, Tan Z, Wierda WG, Eldeib A, Zhang S, Kornblau S, Gandhi V. Mechanisms of MCL-1 Protein Stability Induced by MCL-1 Antagonists in B-Cell Malignancies. Clin Cancer Res 29(2):446-457, 2023. PMID: 36346691.
32. Wierda WG, Kipps TJ, Al-Sawaf O, Chyla B, Biondo JML, Mun Y, Jiang Y, Seymour JF. Utility of measurable residual disease for predicting treatment outcomes with BCR- and BCL2-Targeted therapies in patients with CLL. Leuk Lymphoma 63(12):1-20, 2022. e-Pub 2022. PMID: 35983732.
33. Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, Leguay T, Bishop MR, Topp MS, Tzachanis D, O'Dwyer KM, Arellano ML, Lin Y, Baer MR, Schiller GJ, Park JH, Subklewe M, Abedi M, Minnema MC, Wierda WG, DeAngelo DJ, Stiff P, Jeyakumar D, Dong J, Adhikary S, Zhou L, Schuberth PC, Faghmous I, Masouleh BK, Houot R. Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study. J Hematol Oncol 15(1):170, 2022. e-Pub 2022. PMID: 36494725.
34. Barr PM, Tedeschi A, Wierda WG, Allan JN, Ghia P, Vallisa D, Jacobs R, O'Brien S, Grigg AP, Walker P, Zhou C, Ninomoto J, Krigsfeld G, Tam CS. Effective Tumor Debulking With Ibrutinib Before Initiation of Venetoclax: Results From the CAPTIVATE Minimal Residual Disease (MRD) and Fixed-Duration (FD) Cohorts. Clin Cancer Res 28(20):4385-4391, 2022. e-Pub 2022. PMID: 35939599.
35. Wierda WG, Pagel JM, Davids MS, Zinzani PL, Lu Y, Liu H, Shahda S, Leow CC, Tam CS, Woyach J, Eyre TA, Mato AR. CLL-116 BRUIN CLL-322: A Phase 3 Open-Label, Randomized Study of Fixed-Duration Pirtobrutinib Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Trial in Progress). Clin Lymphoma Myeloma Leuk 22(Suppl 2):S267, 2022. PMID: 36163870.
36. Coombs CC, Pagel JM, Shah NN, Lamanna N, Munir T, Lech-Maranda E, Eyre TA, Woyach JA, Wierda WG, Cheah CY, Cohen JB, Roeker LE, Patel MR, Fakhri B, Barve MA, Tam CS, Lewis D, Gerson JN, Alencar A, Ujjani C, Flinn I, Sundaram S, Ma S, Jagadeesh D, Rhodes J, Taylor J, Abdel-Wahab O, Ghia P, Schuster SJ, Wang D, Nair B, Zhu E, Tsai DE, Davids MS, Brown JR, Jurczak W, Mato AR. CLL-120 Pirtobrutinib, A Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN Study. Clin Lymphoma Myeloma Leuk 22(Suppl 2):S268-S269, 2022. PMID: 36163872.
37. Rozovski U, Veletik I, Harris D, Li P, Liu Z, Jain P, Manshouri T, Ferrajoli A, Burger J, Bose P, Thompson P, Jain N, Wierda W, Verstovsek S, Keating M, Estrov Z. CLL-162 PTX3 is Constitutively Active in CLL Cells. Clin Lymphoma Myeloma Leuk 22(Suppl 2):S271, 2022. PMID: 36163878.
38. Timofeeva N, Jain N, Irajizad E, Aslan B, Katayama H, Cai Y, Ayres M, Iles L, Vykoukal J, Dennison J, Hanash S, Wierda W, Gandhi V. CLL-532 Changes in Proteome of CLL (Chronic Lymphocytic Leukemia) Lymphocytes During Investigator-Initiated Trial of Ibrutinib Alone and in Combination With Venetoclax in Treatment-Naïve Patients With CLL. Clin Lymphoma Myeloma Leuk 22(Suppl 2):S283, 2022. PMID: 36163901.
39. Thompson PA, Jiang X, Banerjee P, Basar R, Garg N, Chen K, Kaplan M, Nandivada V, Cortes AKN, Ferrajoli A, Keating MJ, Peterson CB, Andreeff M, Rezvani K, Wierda WG. A phase two study of high dose blinatumomab in Richter's syndrome. Leukemia 36(9):2228-2232, 2022. e-Pub 2022. PMID: 35941212.
40. Cherng HJ, Khwaja R, Kanagal-Shamanna R, Tang G, Burger J, Thompson P, Ferrajoli A, Estrov Z, Sasaki K, Sampath D, Wang X, Kantarjian H, Keating M, Wierda WG, Jain N. TP53-altered CLL Treated with Firstline Bruton's Tyrosine Kinase Inhibitor-based Therapy: A Retrospective Analysis. Am J Hematol 97(8):1005-1012, 2022. e-Pub 2022. PMID: 35567779.
41. Tettamanti S, Rotiroti MC, Giordano Attianese GMP, Arcangeli S, Zhang R, Banerjee P, Galletti G, McManus S, Mazza M, Nicolini F, Martinelli G, Ivan C, Veliz Rodriguez T, Barbaglio F, Scarfò L, Ponzoni M, Wierda W, Gandhi V, Keating M, Biondi A, Caligaris-Cappio F, Biagi E, Ghia P, Bertilaccio MTS. Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia. Leuk Lymphoma 63(7):1566-1579, 2022. e-Pub 2022. PMID: 35259043.
42. Tam CS, Allan JN, Siddiqi T, Kipps TJ, Jacobs R, Opat S, Barr PM, Tedeschi A, Trentin L, Bannerji R, Jackson S, Kuss BJ, Moreno C, Szafer-Glusman E, Russell K, Zhou C, Ninomoto J, Dean JP, Wierda WG, Ghia P. Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. Blood 139(22):3278-3289, 2022. e-Pub 2022. PMID: 35196370.
43. Chen R, Chen Y, Xiong P, Zheleva D, Blake D, Keating MJ, Wierda WG, Plunkett W. Cyclin-dependent kinase inhibitor fadraciclib (CYC065) depletes anti-apoptotic protein and synergizes with venetoclax in primary chronic lymphocytic leukemia cells. Leukemia 36(6):1596-1608, 2022. e-Pub 2022. PMID: 35383271.
44. Rozovski U, Veletic I, Harris DM, Li P, Liu Z, Jain P, Manshouri T, Ferrajoli A, Burger JA, Bose P, Thompson PA, Jain N, Wierda WG, Verstovsek S, Keating MJ, Estrov Z. STAT3 Activates the Pentraxin 3 Gene in Chronic Lymphocytic Leukemia Cells. J Immunol 208(12):2847-2855, 2022. e-Pub 2022. PMID: 35595309.
45. Short NJ, Macaron W, Konopleva M, Ravandi F, Jain N, Issa GC, Kadia T, Sasaki K, Kebriaei P, Yilmaz M, Thompson PA, Takahashi K, Abbas HA, Wierda WG, Garris R, Kantarjian HM, Jabbour E. Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab. Am J Hematol 97(6):E201-E204, 2022. e-Pub 2022. PMID: 35266566.
46. Wierda WG, Brown J, Abramson JS, Awan F, Bilgrami SF, Bociek G, Brander D, Chanan-Khan AA, Coutre SE, Davis RS, Eradat H, Fletcher CD, Gaballa S, Ghobadi A, Hamid MS, Hernandez-Ilizaliturri F, Hill B, Kaesberg P, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Ma S, Mato A, Mosse C, Schuster S, Siddiqi T, Stephens DM, Ujjani C, Wagner-Johnston N, Woyach JA, Ye JC, Dwyer MA, Sundar H. NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022. J Natl Compr Canc Netw 20(6):622-634, 2022. PMID: 35714675.
47. Cacace F, Iula R, De Novellis D, Caprioli V, D'Amico MR, De Simone G, Cuccurullo R, Wierda WG, Mahadeo KM, Menna G, Tambaro FP. High-Risk Acute Myeloid Leukemia: A Pediatric Prospective. Biomedicines 10(6), 2022. e-Pub 2022. PMID: 35740427.
48. Vaca AM, Ioannou N, Sivina M, Vlachonikola E, Clise-Dwyer K, Kim E, Li D, Ma Q, Ferrajoli A, Estrov Z, Wierda WG, Patten PEM, Ramsay AG, Burger JA. Activation and expansion of T-follicular helper cells in chronic lymphocytic leukemia nurselike cell co-cultures. Leukemia 36(5):1324-1335, 2022. e-Pub 2022. PMID: 35149845.
49. Jelloul FZ, Yang R, Garces S, Kanagal-Shamanna R, Ok CY, Loghavi S, Routbort MJ, Zuo Z, Yin CC, Floyd K, Bassett RL, Wierda W, Jain N, Thompson P, Luthra R, Medeiros LJ, Patel KP. Landscape of NOTCH1 mutations and co-occurring biomarker alterations in chronic lymphocytic leukemia. Leuk Res 116:106827, 2022. e-Pub 2022. PMID: 35430388.
50. Aslan B, Kismali G, Iles LR, Manyam GC, Ayres ML, Chen LS, Gagea M, Bertilaccio MTS, Wierda WG, Gandhi V. Pirtobrutinib inhibits wild-type and mutant Bruton's tyrosine kinase-mediated signaling in chronic lymphocytic leukemia. Blood Cancer J 12(5):80, 2022. e-Pub 2022. PMID: 35595730.
51. Sharman JP, Biondo JML, Boyer M, Fischer K, Hallek M, Jiang D, Kater AP, Porro Lurà M, Wierda WG. A review of the incidence of tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with venetoclax and debulking strategies. EJHaem 3(2):492-506, 2022. e-Pub 2022. PMID: 35846043.
52. Allan JN, Pinilla-Ibarz J, Gladstone DE, Patel K, Sharman JP, Wierda WG, Choi MY, O'Brien SM, Shadman M, Davids MS, Pagel JM, Yimer HA, Ward R, Acton G, Taverna P, Combs DL, Fox JA, Furman RR, Brown JR. Phase 1b dose-escalation study of the selective, noncovalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies. Haematologica 107(4):984-987, 2022. e-Pub 2022. PMID: 34937320.
53. Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, Kamdar M, Munir T, Walewska R, Corbett G, Fogliatto LM, Herishanu Y, Banerji V, Coutre S, Follows G, Walker P, Karlsson K, Ghia P, Janssens A, Cymbalista F, Woyach JA, Ferrant E, Wierda WG, Munugalavadla V, Yu T, Wang MH, Byrd JC. Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia. Leukemia 36(4):1171-1175, 2022. e-Pub 2022. PMID: 34974526.
54. Mukherjee A, Milton DR, Jabbour EJ, Gulbis AM, Kadia T, Jain N, Ledesma C, Burger J, Ferrajoli A, Wierda W, Medeiros LJ, Kantarjian H, Champlin R, Khouri IF. Clinical outcome of allogeneic stem cell transplantation in patients with B-cell lymphoid malignancies following treatment with targeted small molecule inhibitors. Leuk Lymphoma 63(4):1-9, 2022. e-Pub 2022. PMID: 35225133.
55. van Dijk AD, Griffen TL, Qiu YH, Hoff FW, Toro E, Ruiz K, Ruvolo PP, Lillard JW, de Bont ESJM, Burger JA, Wierda W, Kornblau SM. RPPA-based proteomics recognizes distinct epigenetic signatures in chronic lymphocytic leukemia with clinical consequences. Leukemia 36(3):712-722, 2022. e-Pub 2021. PMID: 34625713.
56. Ramos Perez JM, Patel KP, Loghavi S, Garcia-Manero G, Borthakur G, Jabbour E, Wierda W, Pierce S, Brandt M, Kornblau S, Kadia T, Daver N, DiNardo CD, Jain N, Yilmaz M, Short N, Verstovsek S, Ferrajoli A, Andreeff M, Konopleva M, Rivera D, McCue D, Kantarjian HM, Ravandi F. Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapy. Leuk Lymphoma 63(3):1-4, 2022. e-Pub 2021. PMID: 34668451.
57. Siddiqi T, Soumerai JD, Dorritie KA, Stephens DM, Riedell PA, Arnason J, Kipps TJ, Gillenwater HH, Gong L, Yang L, Ogasawara K, Thorpe J, Wierda WG. Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. Blood 139(12):1794-1806, 2022. e-Pub 2021. PMID: 34699592.
58. Jelloul FZ, Yang RK, Wang P, Garces S, Kanagal-Shamanna R, Ok CY, Loghavi S, Routbort MJ, Zuo Z, Yin CC, Floyd K, Bassett RL, Wierda WG, Jain N, Thompson PA, Luthra R, Medeiros LJ, Patel KP. Non-Coding NOTCH1 Mutations in Chronic Lymphocytic Leukemia Negatively Impact Prognosis. Am J Hematol 97(3):E100-E102, 2022. e-Pub 2022. PMID: 34989420.
59. Griffen TL, Hoff FW, Qiu Y, Lillard JW, Ferrajoli A, Thompson P, Toro E, Ruiz K, Burger J, Wierda W, Kornblau SM. Proteomic profiling based classification of CLL provides prognostication for modern therapy and identifies novel therapeutic targets. Blood Cancer J 12(3):43, 2022. e-Pub 2022. PMID: 35301276.
60. Galan-Cobo A, Stellrecht CM, Yilmaz E, Yang C, Qian Y, Qu X, Akhter I, Ayres ML, Fan Y, Tong P, Diao L, Ding J, Giri U, Gudikote J, Nilsson M, Wierda WG, Wang J, Skoulidis F, Minna JD, Gandhi V, Heymach JV. Enhanced vulnerability of LKB1-deficient NSCLC to disruption of ATP pools and redox homeostasis by 8-Cl-Ado. Mol Cancer Res 20(2):280-292, 2022. e-Pub 2021. PMID: 34654720.
61. Aslan B, Hubner SE, Fox JA, Taverna P, Wierda WG, Kornblau SM, Gandhi V. Vecabrutinib inhibits B-cell receptor signal transduction in chronic lymphocytic leukemia cell types with wild-type or mutant Bruton's tyrosine kinase. Haematologica 107(1):292-297, 2022. e-Pub 2022. PMID: 34498444.
62. Kantarjian HM, Jain N, Garcia-Manero G, Welch MA, Ravandi F, Wierda WG, Jabbour EJ. The cure of leukemia through the optimist's prism. Cancer 128(2):240-259, 2022. e-Pub 2021. PMID: 34614211.
63. Yi X, Jain N, Iles LR, Ayres ML, Wierda WG, Gandhi V. Targeting Mcl-1 by AMG-176 During Ibrutinib and Venetoclax Therapy in Chronic Lymphocytic Leukemia. Front Oncol 12:833714, 2022. e-Pub 2022. PMID: 35273915.
64. Jain N, Thompson P, Burger J, Ferrajoli A, Takahashi K, Estrov Z, Borthakur G, Bose P, Kadia T, Pemmaraju N, Sasaki K, Konopleva M, Jabbour E, Garg N, Wang X, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang S, Lopez W, Ayala A, Plunkett W, Gandhi V, Kantarjian H, O'Brien S, Keating M, Wierda WG. Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. Leukemia 35(12):3421-3429, 2021. e-Pub 2021. PMID: 34007049.
65. Sivina M, Kim E, Wierda WG, Ferrajoli A, Jain N, Thompson P, Kantarjian H, Keating M, Burger JA. Ibrutinib induces durable remissions in treatment-naïve patients with CLL and 17p deletion/TP53 mutations. Blood 138(24):2589-2592, 2021. e-Pub 2021. PMID: 34521099.
66. Wierda WG, Allan JN, Siddiqi T, Kipps TJ, Opat S, Tedeschi A, Badoux XC, Kuss BJ, Jackson S, Moreno C, Jacobs R, Pagel JM, Flinn I, Pak Y, Zhou C, Szafer-Glusman E, Ninomoto J, Dean JP, James DF, Ghia P, Tam CS. Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study. J Clin Oncol 39(34):JCO2100807, 2021. e-Pub 2021. PMID: 34618601.
67. Eyre TA, Schuh A, Wierda WG, Brown JR, Ghia P, Pagel JM, Furman RR, Cheung J, Hamdy A, Izumi R, Patel P, Wang MH, Xu Y, Byrd JC, Hillmen P. Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1-2 study. Lancet Haematol 8(12):e912-e921, 2021. e-Pub 2021. PMID: 34735860.
68. De Novellis D, Cacace F, Caprioli V, Wierda WG, Mahadeo KM, Tambaro FP. The TKI Era in Chronic Leukemias. Pharmaceutics 13(12), 2021. e-Pub 2021. PMID: 34959482.
69. Tambaro FP, Singh H, Jones E, Rytting M, Mahadeo KM, Thompson P, Daver N, DiNardo C, Kadia T, Garcia-Manero G, Chan T, Shah RR, Wierda WG. Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia. Leukemia 35(11):3282-3286, 2021. e-Pub 2021. PMID: 33833386.
70. Wierda WG, Rawstron A, Cymbalista F, Badoux X, Rossi D, Brown JR, Egle A, Abello V, Cervera Ceballos E, Herishanu Y, Mulligan SP, Niemann CU, Diong CP, Soysal T, Suzuki R, Tran HTT, Wu SJ, Owen C, Stilgenbauer S, Ghia P, Hillmen P. Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations. Leukemia 35(11):3059-3072, 2021. e-Pub 2021. PMID: 34168283.
71. Esposito CL, Van Roosbroeck K, Santamaria G, Rotoli D, Sandomenico A, Wierda WG, Ferrajoli A, Ruvo M, Calin GA, de Franciscis V, Catuogno S. Selection of a Nuclease-Resistant RNA Aptamer Targeting CD19. Cancers (Basel) 13(20), 2021. e-Pub 2021. PMID: 34680368.
72. Davids MS, Roberts AW, Kenkre VP, Wierda WG, Kumar A, Kipps TJ, Boyer M, Salem AH, Pesko JC, Arzt JA, Mantas M, Kim SY, Seymour JF. Long-term Follow-up of Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study. Clin Cancer Res 27(17):4690-4695, 2021. e-Pub 2021. PMID: 34083230.
73. Sasaki K, Kantarjian HM, Short NJ, Samra B, Khoury JD, Kanagal Shamanna R, Konopleva M, Jain N, DiNardo CD, Khouri R, Garcia-Manero G, Kadia TM, Wierda WG, Khouri IF, Kebriaei P, Mehta RS, Champlin RE, Garris R, Cheung CM, Daver N, Thompson PA, Yilmaz M, Ravandi F, Jabbour E. Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors. Cancer 127(15):2648-2656, 2021. e-Pub 2021. PMID: 33793964.
74. Swaminathan M, Kantarjian HM, Levis M, Guerra V, Borthakur G, Alvarado Y, DiNardo CD, Kadia T, Garcia-Manero G, Ohanian M, Daver N, Konopleva M, Pemmaraju N, Ferrajoli A, Andreeff M, Jain N, Estrov Z, Jabbour EJ, Wierda WG, Pierce S, Pinsoy MR, Xiao L, Ravandi F, Cortes JE. A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Haematologica 106(8):2121-2130, 2021. e-Pub 2021. PMID: 33853292.
75. Jain N, Keating M, Thompson P, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Estrov Z, Sasaki K, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang SA, Garg N, Wang X, Wei C, Cruz N, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda WG. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial. JAMA Oncol 7(8):1213-1219, 2021. PMID: 34110383.
76. Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, Leguay T, Bishop MR, Topp MS, Tzachanis D, O'Dwyer KM, Arellano ML, Lin Y, Baer MR, Schiller GJ, Park JH, Subklewe M, Abedi M, Minnema MC, Wierda WG, DeAngelo DJ, Stiff P, Jeyakumar D, Feng C, Dong J, Shen T, Milletti F, Rossi JM, Vezan R, Masouleh BK, Houot R. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet 398(10299):491-502, 2021. e-Pub 2021. PMID: 34097852.
77. Ragoonanan D, Khazal SJ, Abdel-Azim H, McCall D, Cuglievan B, Tambaro FP, Ahmad AH, Rowan CM, Gutierrez C, Schadler K, Li S, Di Nardo M, Chi L, Gulbis AM, Shoberu B, Mireles ME, McArthur J, Kapoor N, Miller J, Fitzgerald JC, Tewari P, Petropoulos D, Gill JB, Duncan CN, Lehmann LE, Hingorani S, Angelo JR, Swinford RD, Steiner ME, Hernandez Tejada FN, Martin PL, Auletta J, Choi SW, Bajwa R, Dailey Garnes N, Kebriaei P, Rezvani K, Wierda WG, Neelapu SS, Shpall EJ, Corbacioglu S, Mahadeo KM. Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer. Nat Rev Clin Oncol 18(7):435-453, 2021. e-Pub 2021. PMID: 33608690.
78. Ragoonanan D, Khazal SJ, Abdel-Azim H, McCall D, Cuglievan B, Tambaro FP, Ahmad AH, Rowan CM, Gutierrez C, Schadler K, Li S, Di Nardo M, Chi L, Gulbis AM, Shoberu B, Mireles ME, McArthur J, Kapoor N, Miller J, Fitzgerald JC, Tewari P, Petropoulos D, Gill JB, Duncan CN, Lehmann LE, Hingorani S, Angelo JR, Swinford RD, Steiner ME, Tejada FNH, Martin PL, Auletta J, Choi SW, Bajwa R, Garnes ND, Kebriaei P, Rezvani K, Wierda WG, Neelapu SS, Shpall EJ, Corbacioglu S, Mahadeo KM. Author Correction: Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer. Nat Rev Clin Oncol 18(7):468, 2021. e-Pub 2021. PMID: 33731864.
79. Shah BD, Bishop MR, Oluwole OO, Logan AC, Baer MR, Donnellan WB, O'Dwyer KM, Holmes H, Arellano ML, Ghobadi A, Pagel JM, Lin Y, Cassaday RD, Park JH, Abedi M, Castro JE, DeAngelo DJ, Malone AK, Mawad R, Schiller GJ, Rossi JM, Bot A, Shen T, Goyal L, Jain RK, Vezan R, Wierda WG. KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. Blood 138(1):11-22, 2021. e-Pub 2021. PMID: 33827116.
80. Cherng HJ, Jammal N, Paul S, Wang X, Sasaki K, Thompson P, Burger J, Ferrajoli A, Estrov Z, O'Brien S, Keating M, Wierda WG, Jain N. Clinical and molecular characteristics and treatment patterns of adolescent and young adult patients with chronic lymphocytic leukaemia. Br J Haematol 194(1):61-68, 2021. e-Pub 2021. PMID: 33973230.
81. Sivina M, Xiao L, Kim E, Vaca A, Chen SS, Keating MJ, Ferrajoli A, Estrov Z, Jain N, Wierda WG, Huang X, Chiorazzi N, Burger JA. CXCL13 plasma levels function as a biomarker for disease activity in patients with chronic lymphocytic leukemia. Leukemia 35(6):1610-1620, 2021. e-Pub 2020. PMID: 33087831.
82. Byrd JC, Woyach JA, Furman RR, Martin P, O'Brien S, Brown JR, Stephens DM, Barrientos JC, Devereux S, Hillmen P, Pagel JM, Hamdy A, Izumi R, Patel P, Wang MH, Jain N, Wierda WG. Acalabrutinib in Treatment-Naïve Chronic Lymphocytic Leukemia. Blood 137(24):3327-3338, 2021. e-Pub 2021. PMID: 33786588.
83. Marques-Piubelli ML, Schlette EJ, Khoury JD, Furqan F, Vega F, Soto LMS, Wistuba II, Wierda WG, Konopleva M, Ferrajoli A, Strati P. Expression of BCL2 alternative proteins and association with outcome in CLL patients treated with venetoclax. Leuk Lymphoma 62(5):1-10, 2021. e-Pub 2020. PMID: 33327833.
84. Morita K, Jabbour E, Ravandi F, Borthakur G, Khoury JD, Hu S, Garcia-Manero G, Wierda W, Issa G, Daver N, Pemmaraju N, Montalban-Bravo G, Soltysiak KA, Pierce S, Bueso-Ramos C, Cortes J, Sasaki K. Clinical Outcomes of Patients With Chronic Myeloid Leukemia With Concurrent Core Binding Factor Rearrangement and Philadelphia Chromosome. Clin Lymphoma Myeloma Leuk 21(5):338-344, 2021. e-Pub 2021. PMID: 33597098.
85. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Manshouri T, Veletic I, Ferrajoli A, Bose P, Thompson P, Jain N, Verstovsek S, Wierda W, Keating MJ, Estrov Z. STAT3 induces the expression of GLI1 in chronic lymphocytic leukemia cells. Oncotarget 12(5):401-411, 2021. e-Pub 2021. PMID: 33747356.
86. Mato AR, Shah NN, Jurczak W, Cheah CY, Pagel JM, Woyach JA, Fakhri B, Eyre TA, Lamanna N, Patel MR, Alencar A, Lech-Maranda E, Wierda WG, Coombs CC, Gerson JN, Ghia P, Le Gouill S, Lewis DJ, Sundaram S, Cohen JB, Flinn IW, Tam CS, Barve MA, Kuss B, Taylor J, Abdel-Wahab O, Schuster SJ, Palomba ML, Lewis KL, Roeker LE, Davids MS, Tan XN, Fenske TS, Wallin J, Tsai DE, Ku NC, Zhu E, Chen J, Yin M, Nair B, Ebata K, Marella N, Brown JR, Wang M. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet 397(10277):892-901, 2021. PMID: 33676628.
87. Chen R, Tsai J, Thompson PA, Chen Y, Xiong P, Liu C, Burrows F, Sivina M, Burger JA, Keating MJ, Wierda WG, Plunkett W. The multi-kinase inhibitor TG02 induces apoptosis and blocks B-cell receptor signaling in chronic lymphocytic leukemia through dual mechanisms of action. Blood Cancer J 11(3):57, 2021. e-Pub 2021. PMID: 33714981.
88. Gopalakrishnan S, Wierda W, Chyla B, Menon R, Miles D, Humerickhouse R, Awni W, Salem AH, Mensing S, Freise KJ. Integrated Mechanistic Model of Minimal Residual Disease Kinetics With Venetoclax Therapy in Chronic Lymphocytic Leukemia. Clin Pharmacol Ther 109(2):424-432, 2021. e-Pub 2020. PMID: 32749675.
89. Sasaki K, Jabbour EJ, Ravandi F, Konopleva M, Borthakur G, Wierda WG, Daver N, Takahashi K, Naqvi K, DiNardo C, Montalban-Bravo G, Kanagal-Shamanna R, Issa G, Jain P, Skinner J, Rios MB, Pierce S, Soltysiak KA, Sato J, Garcia-Manero G, Cortes JE. The LEukemia Artificial Intelligence Program (LEAP) in Chronic Myeloid Leukemia in Chronic Phase: A Model to Improve Patient Outcomes. Am J Hematol 96(2):241-250, 2021. e-Pub 2020. PMID: 33180322.
90. Maiti A, DiNardo CD, Daver NG, Rausch CR, Ravandi F, Kadia TM, Pemmaraju N, Borthakur G, Bose P, Issa GC, Short NJ, Yilmaz M, Montalban-Bravo G, Ferrajoli A, Jabbour EJ, Jain N, Ohanian M, Takahashi K, Thompson PA, Loghavi S, Montalbano KS, Pierce S, Wierda WG, Kantarjian HM, Konopleva MY. Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. Blood Cancer J 11(2):25, 2021. e-Pub 2021. PMID: 33563904.
91. Paul S, Rausch CR, Jain N, Kadia T, Ravandi F, DiNardo CD, Welch MA, Dabaja BS, Daver N, Garcia-Manero G, Wierda W, Pemmaraju N, Montalban Bravo G, Thompson P, Verstovsek S, Konopleva M, Kantarjian H, Jabbour E. Treating Leukemia in the Time of COVID-19. Acta Haematol 144(2):1-13, 2021. e-Pub 2020. PMID: 32392559.
92. Abbas HA, Wierda WG. Acalabrutinib: A Selective Bruton Tyrosine Kinase Inhibitor for the Treatment of B-Cell Malignancies. Front Oncol 11:668162, 2021. e-Pub 2021. PMID: 34055635.
93. O'Brien SM, Brown JR, Byrd JC, Furman RR, Ghia P, Sharman JP, Wierda WG. Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice. Front Oncol 11:720704, 2021. e-Pub 2021. PMID: 34858810.
94. Tambaro FP, De Novellis D, Wierda WG. The Role of BTK Inhibition in the Treatment of Chronic Lymphocytic Leukemia: A Clinical View. J Exp Pharmacol 13:923-935, 2021. e-Pub 2021. PMID: 34744463.
95. Major CK, Kantarjian H, Sasaki K, Borthakur G, Kadia T, Pemmaraju N, DiNardo C, Short NJ, Daver N, Jabbour E, Champlin R, Garcia-Manero G, Konopleva M, Andreeff M, Kornblau S, Wierda W, Pierce S, Ravandi F, Cortes J. Survivorship in AML - a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years. Leuk Lymphoma 61(13):1-8, 2020. e-Pub 2020. PMID: 32755333.
96. Issa GC, Kantarjian HM, Xiao L, Ning J, Alvarado Y, Borthakur G, Daver N, DiNardo CD, Jabbour E, Bose P, Jain N, Kadia TM, Naqvi K, Pemmaraju N, Takahashi K, Verstovsek S, Andreeff M, Kornblau SM, Estrov Z, Ferrajoli A, Garcia-Manero G, Ohanian M, Wierda WG, Ravandi F, Cortes JE. Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. Leukemia 34(11):2914-2924, 2020. e-Pub 2020. PMID: 32546726.
97. Frei M, Aitken SL, Jain N, Thompson P, Wierda W, Kontoyiannis DP, DiPippo AJ. Incidence and characterization of fungal infections in chronic lymphocytic leukemia patients receiving ibrutinib. Leuk Lymphoma 61(10):1-4, 2020. e-Pub 2020. PMID: 32530347.
98. Tambaro FP, Khazal S, Nunez C, Ragoonanan D, Tewari P, Petropoulos D, Kebriaei P, Wierda WG, Mahadeo KM. Complete remission in refractory acute lymphoblastic leukemia using blinatumomab after failure of response to CD-19 chimeric antigen receptor T-cell therapy. Clin Case Rep 8(9):1678-1681, 2020. e-Pub 2020. PMID: 32983475.
99. Hampel PJ, Cherng HJ, Call TG, Ding W, Khanlari M, McPhail ED, Miranda RN, Lin P, Tawbi HA, Ferrajoli A, Wierda WG, Jain N, Parikh SA. Incidental Richter transformation in chronic lymphocytic leukemia patients during temporary interruption of ibrutinib. Blood Adv 4(18):4508-4511, 2020. PMID: 32946567.
100. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum K, Sharman JP, Wierda W, Zhao W, Heerema NA, Luan Y, Liu EA, Dean JP, O'Brien S. Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study. Clin Cancer Res 26(15):3918-3927, 2020. e-Pub 2020. PMID: 32209572.
101. Yi X, Sarkar A, Kismali G, Aslan B, Ayres M, Iles LR, Keating MJ, Wierda WG, Long JP, Bertilaccio MTS, Gandhi V. AMG-176, an Mcl-1 antagonist, shows preclinical efficacy in chronic lymphocytic leukemia. Clin Cancer Res 26(14):3856-3867, 2020. e-Pub 2020. PMID: 31937611.
102. Sasaki K, Kantarjian H, Wierda W, Ravandi-Kashani F, Jorgensen J, Wang SA, Khoury J, Daver N, Burger J, Di Nardo CD, Jain N, Short NJ, Estrov Md Z, Konopleva Md PhD M, Ohanian DO M, Garcia-Manero G, Kadia T, Alvarado-Valero Y, Yilmaz M, Pierce S, Garris R, Ingram A, Cortes J, O'Brien S, Jabbour E. Phase 2 study of hyper-CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia. Am J Hematol 95(7):734-739, 2020. e-Pub 2020. PMID: 32170867.
103. Kim E, Ten Hacken E, Sivina M, Clarke A, Thompson PA, Jain N, Ferrajoli A, Estrov Z, Keating MJ, Wierda WG, Bhalla KN, Burger JA. The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment. Leukemia 34(6):1588-1598, 2020. e-Pub 2019. PMID: 31862959.
104. Condoluci A, Terzi di Bergamo L, Langerbeins P, Hoechstetter MA, Herling CD, De Paoli L, Delgado J, Rabe KG, Gentile M, Doubek M, Mauro FR, Chiodin G, Mattsson M, Bahlo J, Cutrona G, Kotaskova J, Deambrogi C, Smedby KE, Spina V, Bruscaggin A, Wu W, Moia R, Bianchi E, Gerber B, Zucca E, Gillessen S, Ghielmini M, Cavalli F, Stussi G, Hess MA, Baumann TS, Neri A, Ferrarini M, Rosenquist R, Forconi F, Foà R, Pospisilova S, Morabito F, Stilgenbauer S, Döhner H, Parikh SA, Wierda WG, Montserrat E, Gaidano G, Hallek M, Rossi D. International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. Blood 135(21):1859-1869, 2020. PMID: 32267500.
105. Wierda WG, Tambaro FP. How I manage CLL with venetoclax-based treatments. Blood 135(17):1421-1427, 2020. PMID: 32076705.
106. Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, Kamdar M, Munir T, Walewska R, Corbett G, Fogliatto LM, Herishanu Y, Banerji V, Coutre S, Follows G, Walker P, Karlsson K, Ghia P, Janssens A, Cymbalista F, Woyach JA, Salles G, Wierda WG, Izumi R, Munugalavadla V, Patel P, Wang MH, Wong S, Byrd JC. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet 395(10232):1278-1291, 2020. PMID: 32305093.
107. Maiti A, Kantarjian HM, Popat V, Borthakur G, Garcia-Manero G, Konopleva MY, DiNardo CD, Verstovsek S, Andreeff M, Kadia TM, Ajufo HO, Goswamy RV, Blanco C, Velasquez M, Daver NG, Pemmaraju N, Pierce SR, Wierda WG, Kornblau SM, Ravandi F, Cortes JE. Clinical value of event-free survival in acute myeloid leukemia. Blood Adv 4(8):1690-1699, 2020. PMID: 32330243.
108. Byrd JC, Wierda WG, Schuh A, Devereux S, Chaves JM, Brown JR, Hillmen P, Martin P, Awan FT, Stephens DM, Ghia P, Barrientos J, Pagel JM, Woyach JA, Burke K, Covey T, Gulrajani M, Hamdy A, Izumi R, Frigault MM, Patel P, Rothbaum W, Wang MH, O'Brien S, Furman RR. Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results. Blood 135(15):1204-1213, 2020. PMID: 31876911.
109. Srour SA, Singh H, McCarty J, de Groot E, Huls H, Rondon G, Qazilbash M, Ciurea S, Bardelli G, Buck J, Alousi A, Nieto Y, Rezvani K, Marin D, Popat U, Hosing C, Shpall EJ, Wierda WG, Kantarjian H, Champlin RE, Cooper LJ, Kebriaei P. Long-term outcomes of Sleeping Beauty generated CD19specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas. Blood 135(11):862-865, 2020. e-Pub 2020. PMID: 31961918.
110. Strati P, Schlette EJ, Solis Soto LM, Duenas DE, Sivina M, Kim E, Keating MJ, Wierda WG, Ferrajoli A, Kantarjian H, Estrov Z, Jain N, Thompson PA, Wistuba II, Burger JA. Achieving Complete Remission in CLL Patients Treated with Ibrutinib: Clinical Significance and Predictive Factors. Blood 135(7):510-513, 2020. e-Pub 2020. PMID: 31895947.
111. Shah M, Rajha E, DiNardo C, Muckey E, Wierda WG, Yeung SJ. Adverse Events of Novel Therapies for Hematologic Malignancies: What Emergency Physicians Should Know. Ann Emerg Med 75(2):264-286, 2020. e-Pub 2019. PMID: 31561995.
112. Alfayez M, Thakral B, Jain P, Ravandi F, Ferrajoli A, Jain N, Pemmaraju N, Wierda W, Kadia T. First report of clinical response to venetoclax combination with pentostatin in T-cell-prolymphocytic leukemia (T-PLL). Leuk Lymphoma 61(2):445-449, 2020. e-Pub 2019. PMID: 31566032.
113. Yilmaz M, Kantarjian H, Wang X, Khoury JD, Ravandi F, Jorgensen J, Short NJ, Loghavi S, Cortes J, Garcia-Manero G, Kadia T, Sasaki K, Konopleva M, Takahashi K, Wierda W, Jain N, Verstovsek S, Estrov Z, Bose P, Pierce S, Garris R, O'Brien S, Jabbour E. The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival. Am J Hematol 95(2):144-150, 2020. e-Pub 2019. PMID: 31682008.
114. Tambaro FP, Wierda WG. Tumour lysis syndrome in patients with chronic lymphocytic leukaemia treated with BCL-2 inhibitors: risk factors, prophylaxis, and treatment recommendations. Lancet Haematol 7(2):e168-e176, 2020. PMID: 32004486.
115. Wierda WG, Byrd JC, Abramson JS, Bilgrami SF, Bociek G, Brander D, Brown J, Chanan-Khan AA, Chavez JC, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Lim MS, Ma S, Malek S, Mato A, Mosse C, Shadman M, Siddiqi T, Stephens D, Sundaram S, Wagner N, Dwyer M, Sundar H. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 18(2):185-217, 2020. PMID: 32023533.
116. Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, Nassif Kerbauy L, Overman B, Thall P, Kaplan M, Nandivada V, Kaur I, Nunez Cortes A, Cao K, Daher M, Hosing C, Cohen EN, Kebriaei P, Mehta R, Neelapu S, Nieto Y, Wang M, Wierda W, Keating M, Champlin R, Shpall EJ, Rezvani K. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. N Engl J Med 382(6):545-553, 2020. PMID: 32023374.
117. Vitale C, Falchi L, Ciccone M, Burger J, Pemmaraju N, Borthakur G, Wierda WG, Keating MJ, Ferrajoli A. Ofatumumab is safe and effective as front-line treatment in older patients with chronic lymphocytic leukemia and severe co-morbidities, including other malignancies. J Geriatr Oncol 11(1):19-23, 2020. e-Pub 2019. PMID: 31005650.
118. Chen LS, Keating MJ, Wierda WG, Gandhi V. Induction of apoptosis by MCL-1 inhibitors in chronic lymphocytic leukemia cells. Leuk Lymphoma 60(12):1-4, 2019. e-Pub 2019. PMID: 31161836.
119. Banerjee P, Zhang R, Ivan C, Galletti G, Clise-Dwyer K, Barbaglio F, Scarfò L, Aracil M, Klein C, Wierda W, Plunkett W, Caligaris-Cappio F, Gandhi V, Keating MJ, Bertilaccio MTS. Trabectedin Reveals a Strategy of Immunomodulation in Chronic Lymphocytic Leukemia. Cancer Immunol Res 7(12):2036-2051, 2019. e-Pub 2019. PMID: 31530560.
120. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger JA, Bose P, Thompson PA, Jain N, Wierda WG, Uziel O, Keating MJ, Estrov Z. STAT3-Induced Wnt5a Provides Chronic Lymphocytic Leukemia Cells with Survival Advantage. J Immunol 203(11):3078-3085, 2019. e-Pub 2019. PMID: 31645416.
121. Mato AR, Wierda WG, Davids MS, Cheson BD, Coutre SE, Choi M, Furman RR, Heffner L, Barr PM, Eradat H, Ford SM, Zhou L, Verdugo M, Humerickhouse RA, Potluri J, Byrd JC. Utility of PET-CT in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy. Haematologica 104(11):2258-2264, 2019. e-Pub 2019. PMID: 30923097.
122. Hu B, Patel KP, Chen HC, Wang X, Luthra R, Routbort MJ, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson P, Burger J, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating M, Wierda WG. Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patients. Br J Haematol 187(3):307-318, 2019. e-Pub 2019. PMID: 31243771.
123. Lunning M, Vose J, Nastoupil L, Fowler N, Burger JA, Wierda WG, Schreeder MT, Siddiqi T, Flowers CR, Cohen JB, Sportelli P, Miskin HP, Weiss MS, O'Brien S. Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 134(21):1811-1820, 2019. PMID: 31558467.
124. Thompson PA, Srivastava J, Peterson C, Strati P, Jorgensen JL, Hether T, Keating MJ, O'Brien SM, Ferrajoli A, Burger JA, Estrov Z, Jain N, Wierda WG. Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy. Blood 134(22):1951-1959, 2019. PMID: 31537528.
125. Brown JR, Wierda WG. Evolving Strategies in First-Line Chronic Lymphocytic Leukemia: Is There a Role for Chemoimmunotherapy?. J Natl Compr Canc Netw 17(11.5):1408-1410, 2019. PMID: 31766019.
126. Strati P, Wang F, Tambaro FP, Thompson PA, Burger JA, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating MJ, Futreal A, Takahashi K, Wierda WG. The landscape of genetic mutations in patients with chronic lymphocytic leukaemia and complex karyotype. Br J Haematol 187(1):e1-e4, 2019. e-Pub 2019. PMID: 31344256.
127. Guièze R, Liu VM, Rosebrock D, Jourdain AA, Hernández-Sánchez M, Martinez Zurita A, Sun J, Ten Hacken E, Baranowski K, Thompson PA, Heo JM, Cartun Z, Aygün O, Iorgulescu JB, Zhang W, Notarangelo G, Livitz D, Li S, Davids MS, Biran A, Fernandes SM, Brown JR, Lako A, Ciantra ZB, Lawlor MA, Keskin DB, Udeshi ND, Wierda WG, Livak KJ, Letai AG, Neuberg D, Harper JW, Carr SA, Piccioni F, Ott CJ, Leshchiner I, Johannessen CM, Doench J, Mootha VK, Getz G, Wu CJ. Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies. Cancer Cell 36(4):369-384.e13, 2019. e-Pub 2019. PMID: 31543463.
128. Boddu P, Schlette E, Thakral B, Tang G, Pemmaraju N, Kadia T, Ferrajoli A, Ravandi F, Wierda W, Jain N. Acute promyelocytic leukemia in a patient with chronic lymphocytic leukemia-A case report. Hematol Oncol Stem Cell Ther 12(3):161-165, 2019. e-Pub 2017. PMID: 28830803.
129. Yalniz FF, Wierda WG. Targeting BCL2 in Chronic Lymphocytic Leukemia and Other Hematologic Malignancies. Drugs 79(12):1287-1304, 2019. PMID: 31313099.
130. Giacopelli B, Zhao Q, Ruppert AS, Agyeman A, Weigel C, Wu YZ, Gerber MM, Rabe KG, Larson MC, Lu J, Blachly JS, Rogers KA, Wierda WG, Brown JR, Rai KR, Keating M, Rassenti LZ, Kipps TJ, Zenz T, Shanafelt TD, Kay NE, Abruzzo LV, Coombes KR, Woyach JA, Byrd JC, Oakes CC. Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia. Blood 134(8):688-698, 2019. e-Pub 2019. PMID: 31292113.
131. Chen R, Zhu M, Chaudhari RR, Robles O, Chen Y, Skillern W, Qin Q, Wierda WG, Zhang S, Hull KG, Romo D, Plunkett W. Creating novel translation inhibitors to target pro-survival proteins in chronic lymphocytic leukemia. Leukemia 33(7):1663-1674, 2019. e-Pub 2019. PMID: 30700841.
132. Wierda WG, Byrd JC, O'Brien S, Coutre S, Barr PM, Furman RR, Kipps TJ, Burger JA, Stevens DA, Sharman J, Ghia P, Flinn IW, Zhou C, Ninomoto J, James DF, Tam CS. Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia. Br J Haematol 186(1):184-188, 2019. e-Pub 2019. PMID: 30740654.
133. Roberts AW, Ma S, Kipps TJ, Coutre SE, Davids MS, Eichhorst B, Hallek M, Byrd JC, Humphrey K, Zhou L, Chyla B, Nielsen J, Potluri J, Kim SY, Verdugo M, Stilgenbauer S, Wierda WG, Seymour JF. Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables. Blood 134(2):111-122, 2019. e-Pub 2019. PMID: 31023700.
134. Wierda WG, Byrd JC, Davids MS, Furman RR, Cheson BD, Barr PM, Eradat H, Heffner L, Zhou L, Verdugo M, Potluri J, Choi M. Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B-cell receptor pathway inhibitor. Br J Haematol 185(5):961-966, 2019. e-Pub 2018. PMID: 30478940.
135. Hu B, Patel KP, Chen HC, Wang X, Wang F, Luthra R, Routbort MJ, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson P, Burger J, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating MJ, Wierda WG. Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments. Br J Haematol 185(5):852-864, 2019. e-Pub 2019. PMID: 30924136.
136. Flinn IW, Gribben JG, Dyer MJS, Wierda W, Maris MB, Furman RR, Hillmen P, Rogers KA, Iyer SP, Quillet-Mary A, Ysebaert L, Walter HS, Verdugo M, Klein C, Huang H, Jiang Y, Lozanski G, Pignataro DS, Humphrey K, Mobasher M, Kipps TJ. Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia. Blood 133(26):2765-2775, 2019. e-Pub 2019. PMID: 30862645.
137. Paul S, Jain N, Ferrajoli A, O'Brien S, Burger J, Keating M, Wierda W. A phase II trial of eltrombopag for patients with chronic lymphocytic leukaemia (CLL) and thrombocytopenia. Br J Haematol 185(3):606-608, 2019. e-Pub 2018. PMID: 30406944.
138. Sasaki K, Kantarjian HM, O'Brien S, Ravandi F, Konopleva M, Borthakur G, Garcia-Manero G, Wierda WG, Daver N, Ferrajoli A, Takahashi K, Jain P, Rios MB, Pierce SA, Jabbour EJ, Cortes JE. Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors. Int J Hematol 109(5):545-552, 2019. e-Pub 2019. PMID: 30830579.
139. Strati P, Takahashi K, Peterson CB, Keating MJ, Thompson PA, Daver NG, Jain N, Burger JA, Estrov Z, O'Brien SM, Kantarjian HM, Wierda WG, Futreal PA, Ferrajoli A. Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL. Blood Adv 3(9):1533-1539, 2019. PMID: 31076409.
140. Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W. Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med 380(22):2095-2103, 2019. PMID: 31141631.
141. Wierda WG. Does FCR have the potential to cure a subgroup of patients with chronic lymphocytic leukemia?. Clin Adv Hematol Oncol 17(4):214-216, 2019. PMID: 31188811.
142. Cervantes-Gomez F, Stellrecht CM, Ayres ML, Keating MJ, Wierda WG, Gandhi V. PIM kinase inhibitor, AZD1208, inhibits protein translation and induces autophagy in primary chronic lymphocytic leukemia cells. Oncotarget 10(29):2793-2809, 2019. e-Pub 2019. PMID: 31073371.
143. Boddu P, Thakral B, Alhuraiji A, Pemmaraju N, Kadia T, Ohanian M, Ravandi F, Jabbour E, Wierda W, Khoury JD, Jain N. Distinguishing thymoma from T-lymphoblastic leukaemia/lymphoma: a case-based evaluation. J Clin Pathol 72(3):251-257, 2019. e-Pub 2018. PMID: 30467242.
144. Burger JA, Sivina M, Jain N, Kim E, Kadia T, Estrov Z, Nogueras-Gonzalez GM, Huang X, Jorgensen J, Li J, Cheng M, Clow F, Ohanian M, Andreeff M, Mathew T, Thompson P, Kantarjian H, O'Brien S, Wierda WG, Ferrajoli A, Keating MJ. Randomized trial of ibrutinib versus ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood 133(10):1011-1019, 2019. e-Pub 2018. PMID: 30530801.
145. Nastoupil LJ, Lunning MA, Vose JM, Schreeder MT, Siddiqi T, Flowers CR, Cohen JB, Burger JA, Wierda WG, O'Brien S, Sportelli P, Miskin HP, Purdom MA, Weiss MS, Fowler NH. Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial. Lancet Haematol 6(2):e100-e109, 2019. PMID: 30709431.
146. Kanagal-Shamanna R, Jain P, Patel KP, Routbort M, Bueso-Ramos C, Alhalouli T, Khoury JD, Luthra R, Ferrajoli A, Keating M, Jain N, Burger J, Estrov Z, Wierda W, Kantarjian HM, Medeiros LJ. Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation. Cancer 125(4):559-574, 2019. e-Pub 2018. PMID: 30508305.
147. Wierda WG, Byrd JC, Abramson JS, Bilgrami SF, Bociek G, Brander D, Brown J, Chanan-Khan AA, Chavez JC, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Ma S, Malek S, Mato A, Mosse C, Neppalli VT, Shadman M, Siddiqi T, Stephens D, Wagner N, Dwyer MA, Sundar H. NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019. J Natl Compr Canc Netw 17(1):12-20, 2019. PMID: 30659125.
148. Wierda WG, Byrd JC, Abramson JS, Bhat S, Bociek G, Brander D, Brown J, Chanan-Khan A, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Lancet J, Ma S, Malek S, Mosse C, Shadman M, Siddiqi T, Stephens D, Wagner N, Zelenetz AD, Dwyer MA, Sundar H. Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 15(11):1414-1427, 2017. PMID: 29118233.
149. Jain P, Kanagal-Shamanna R, Wierda W, Ferrajoli A, Keating M, Jain N. Membranoproliferative glomerulonephritis and acute renal failure in a patient with chronic lymphocytic leukemia: Response to obinutuzumab. Hematol Oncol Stem Cell Ther 10(3):151-154, 2017. e-Pub 2016. PMID: 27352257.
150. Wierda WG. Updates to the management of chronic lymphocytic leukemia. J Natl Compr Canc Netw 13(5 Suppl):662-5, 2015. PMID: 25995424.
151. Burger JA, Keating MJ, Wierda WG, Hartmann E, Hoellenriegel J, Rosin NY, de Weerdt I, Jeyakumar G, Ferrajoli A, Cardenas-Turanzas M, Lerner S, Jorgensen JL, Nogueras-González GM, Zacharian G, Huang X, Kantarjian H, Garg N, Rosenwald A, O'Brien S. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol 15(10):1090-9, 2014. e-Pub 2014. PMID: 25150798.
152. Strati P, Keating MJ, O'Brien SM, Ferrajoli A, Burger J, Faderl S, Tambaro FP, Jain N, Wierda WG. Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion. Haematologica 99(8):1350-5, 2014. e-Pub 2014. PMID: 24859876.
153. James DF, Werner L, Brown JR, Wierda WG, Barrientos JC, Castro JE, Greaves A, Johnson AJ, Rassenti LZ, Rai KR, Neuberg D, Kipps TJ. Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium. J Clin Oncol 32(19):2067-73, 2014. e-Pub 2014. PMID: 24868031.
154. Claus R, Lucas DM, Ruppert AS, Williams KE, Weng D, Patterson K, Zucknick M, Oakes CC, Rassenti LZ, Greaves AW, Geyer S, Wierda WG, Brown JR, Gribben JG, Barrientos JC, Rai KR, Kay NE, Kipps TJ, Shields P, Zhao W, Grever MR, Plass C, Byrd JC. Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia. Blood 124(1):42-8, 2014. e-Pub 2014. PMID: 24868078.
155. El-Mabhouh AA, Ayres ML, Shpall EJ, Baladandayuthapani V, Keating MJ, Wierda WG, Gandhi V. Evaluation of bendamustine in combination with fludarabine in primary chronic lymphocytic leukemia cells. Blood 123(24):3780-9, 2014. e-Pub 2014. PMID: 24747434.
156. Rozovski U, Wu JY, Harris DM, Liu Z, Li P, Hazan-Halevy I, Ferrajoli A, Burger JA, O'Brien S, Jain N, Verstovsek S, Wierda WG, Keating MJ, Estrov Z. Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic leukemia cells. Blood 123(24):3797-802, 2014. e-Pub 2014. PMID: 24778152.
157. Wodarz D, Garg N, Komarova NL, Benjamini O, Keating MJ, Wierda WG, Kantarjian H, James D, O'Brien S, Burger JA. Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib. Blood 123(26):4132-5, 2014. e-Pub 2014. PMID: 24829205.
158. Ferrajoli A, Shanafelt TD, Ivan C, Shimizu M, Rabe KG, Nouraee N, Ikuo M, Ghosh AK, Lerner S, Rassenti LZ, Xiao L, Hu J, Reuben JM, Calin S, You MJ, Manning JT, Wierda WG, Estrov Z, O'Brien S, Kipps TJ, Keating MJ, Kay NE, Calin GA. Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B-chronic lymphocytic leukemia. Blood 122(11):1891-9, 2013. e-Pub 2013. PMID: 23821659.
159. Falchi L, Keating MJ, Wang X, Coombs CC, Lanasa MC, Strom S, Wierda WG, Ferrajoli A. Clinical characteristics, response to therapy, and survival of African American patients diagnosed with chronic lymphocytic leukemia: Joint experience of the MD Anderson Cancer Center and Duke University Medical Center. Cancer 119(17):3177-85, 2013. e-Pub 2013. PMID: 24022787.
160. Wierda W, Kipps T, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, Robak T, Furman RR, Hillmen P, Trneny M, Dyer MJ, Padmanabham S, Piotrowska M, Kozak T, Chan G, Davis R, Losic N, Wilms J, Russell C, Osterborg A.. Ofatumumab, a Novel CD20 Monoclonal Antibody, Is Active in Patients With Fludarabine-and Alemtuzumab-Refractory or Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia Irrespective of Prior Rituximab. Clin Lymphoma Myeloma 9(6):E36, 2009. PMID: 19951868.
161. Motta M, Wierda WG, Ferrajoli A. Chronic lymphocytic leukemia: treatment options for patients with refractory disease. Cancer 115(17):3830-41, 2009. e-Pub 2009. PMID: 19536902.
162. Wierda WG, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do KA, Garcia-Manero G, Cortes J, Thomas D, Koller C, Burger J, Lerner S, Kantarjian H, Keating M. Characteristics Associated With Important Clinical End Points in Patients With Chronic Lymphocytic Leukemia at Initial Treatment. J Clin Oncol 27(10):1637-43, 2009. e-Pub 2009. PMID: 19224852.
163. Wierda W. New prognostic factors in chronic lymphocytic leukemia. Clin Adv Hematol Oncol 7(1):32-42, 2009. PMID: 19274038.
164. Tam CS, O'Brien S, Lerner S, Khouri I, Ferrajoli A, Faderl S, Browning M, Tsimberidou AM, Kantarjian H, Wierda WG. The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy. Leuk Lymphoma 48(10):1931-1939, 2007. PMID: 17917961.
165. Wierda W, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do K-A, Cortes J, Thomas D, Garcia-Manero G, Koller C, Beran M, Giles F, Ravandi F, Lerner S, Kantarjian H, Keating M.. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood 109(11):4679-4685, 2007. e-Pub 2007. PMID: 17299097.
166. Wierda WG, Kipps J. Gene therapy and active immune therapy of hematologic malignancies. Best Pract Res Clin Haematol 20(3):557-68, 2007.
167. Wierda W, O'Brien S, Faderl S, Ferrajoli A, Wang X, Do KA, Garcia-Manero G, Thomas D, Cortes J, Ravandi-Kashani F, Giles F, Lerner S, Kantarjian H, Keating M. A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens. Cancer 106(2):337-45, 2006. PMID: 16353201.
168. Keating MJ, Rai KR, Wierda WG. Evolution of treatment strategies in chronic lymphocytic leukemia. Part 2 of a 3-Part series: Advances in the treatment of hematologic malignancies. Clin Adv Hematol Oncol 3(8):1-10; quiz 11-2, 2005. PMID: 16201050.
169. Wierda W, O'Brien S, Wen S, Faderl S, Garcia-Manero G, Thomas D, Do KA, Cortes J, Koller C, Beran M, Ferrajoli A, Giles F, Lerner S, Albitar M, Kantarjian H, Keating M. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 23(18):4070-4078, 2005. e-Pub 2005. PMID: 15767647.
170. Wierda WG, Keating MJ, O’Brien S. Refractory chronic lymphocytic leukemia – prognosis and treatment options. Am J Cancer 3(3):163-178, 2004.

Abstracts

1. Short NJ, Jabbour EJ, Senapati J, Nasr LF, Haddad FG, Li Z, Hsiao Y, Yang JJ, Pemmaraju N, Ohanian M, Wierda WG, Montalban-Bravo G, Borthakur G, Han L, Xiao L, Huang X, Abramova R, Zhao M, Garris R, Konopleva M, Ravandi F, Kantarjian HM. A Phase 1/2 Study of Mini-Hyper-CVD plus Venetoclax in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. Blood Advances, 2024.
2. Coombs CC, Woyach JA, Brown JR, Ghia P, Roeker LE, Patel K, Eyre TA, Tam CF, Seymour JF, Shah NN, Flinn IW, Cheah CY, Ma S, Rhodes JM, Izutsu K, Jurczak W, Wierda WG, Loubert A, Payakachat N, Hess LM, Abada P, Lamanna N. Patient-Reported Outcomes (PROs) Among Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Receiving Pirtobrutinib: Analysis from the BRUIN Phase 1/2 Study. Blood 142(Suppp 1):6535, 2023.
3. Thompson PA, Bazinet A, Wierda WG, Tam CS, O’Brien SM, Saha S, Peterson CB, Plunkett W, Keating MJ. Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up. Blood 142(Issue 21):1784-1788, 2023.
4. Rohena DD, Cuesta AP, Slawin B, Ravikrishnan J, Liu C, Williams C, Hu W, Zhang P, Thompson P, Wierda WG, Jain N, Shukla S, Zheng G, Zhou D, Woyach JA, Sampath D. Enriched Signalling Pathways in Venetoclax-Relapsed Chronic Lymphocytic Leukemia (CLL) Cells and Targeting Using a Protac-Based Bcl-2/Bcl-Xl Degrader. Blood 142(Supp 1):4195, 2023.
5. Jain N, Keating MJ, Thompson PA, Ferrajoli A, Senapati J, Burger JA, Borthakur G, Swaminathan M, Takahashi K, Estrov Z, Konopleva MY, Sasaki K, Kadia TM, Pemmaraju N, Daver N, Jabbour E, DiNardo CD, Valero YA, Yilmaz M, Bose P, Ohanian M, Kanagal-Shamanna R, Patel K, Jorgensen JL, Wangn SA, Nassar S, Garg N, Hwang H, Wang X, Cruz N, Ayala A, Plunkett W, Kantarjian HM, Gandhi V, Wierda WG. Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 5-Year Follow-up Data. Blood 142(Supp 1):4635, 2023.
6. Jain N, Thompson P, Jain A, Burger JA, Ferrajoli A, Senapati J, Takahashi K, Swaminathan M, Estrov Z, Borthakur G, Bose P, Kadia TM, Pemmaraju N, Sasaki K, Bansal D, Konopleva MY, Jabbour E, Garg N, Wang X, Kanagal-Shamanna R, Patel KP, Wang W, Wang SA, Jorgensen JL, Lopez W, Ayala A, Plunkett W, Gandhi V, Kantarjian HM, O'Brien SM, Keating MJ,<b> Wierda WG</b>. Ibrutinib, Fludarabine, Cyclophosphamide and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without Del(17p)/ TP53 Mutation: Six-Year Follow-up Analyses. Blood 142(Supp 1):3267, 2023.
7. Jain N, D'Olimpio J, gillis-Smith A, Lee ST, Shah NN, Pinilla-Ibarz J, Coombs CC, Barrientos JC, Ma S, Sawa M, Miyamoto K, Arimura A, Gandhi V, Wierda WG. Trial in Progress: A Phase 1b Study of AS-1763, an Oral, Potent and Selective Noncovalent BTK Inhibitor, in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma. Blood 142(Supp 1):3288, 2023.
8. Woyach JA, Brown JR, Ghia P, Roeker LE, Patel K, Eyre TA, Munir T, Lech-Maranda E, Lamanna N, Tam CS, Seymour JF, Tessoulin B, Shah NN, Ujjani CS, Fakhri B, Coombs CC, Flinn IW, Patel M, Nasta SD, Cohen JB, Alencar AJ, Cheah CY, Ma S, Rhodes JM, Jagadeesh D, Zinzani PL, Osterborg A, Izutsu K, Tsai DE, Abada P, Balbas M, Li J, Ruppert AS, Jurczak W, Wierda WG. Pirtobrutinib in Post-cBTKi CLL/SLL: ~30 Months Follow-up and Subgroup Analysis With/Without Prior BCL2i from the Phase 1/2 BRUIN Study. Blood 142(Supp 1):325, 2023.
9. Shaim H, Rafei H, Kaplan M, Basar R, Daher M, Shanley M, Banerjee P, Kumar B, Nunez Cortes AK, IslamS, Jiang XR, Kerbauy LN, Lin P, Gokdemir E, Uprety N, Acharya S, Mendt MC, Garcia LM, Biederstädt A, Liu B, Liu E, Ang S, Burger JA, Wierda WG, Ferrajoli A, Shpall EJ, Rezvani K. NK Cell Dysfunction in CLL Is Mediated through SHP-1 Signaling and Is Associated with Poor Prognosis. Blood 142(Supp 1):1895, 2023.
10. Bataller A, Kantarjian HM, Kadia TM, Daver N, DiNardo CD, Borthakur G, Short NJ, Yilmaz M, Issa GC, Valero YA, Montalban-Bravo G, Maiti A, Abbas HA, Jabbour E, Wierda WG, Garcia-Manero G, Ravandi F. Mutational and Cytogenetic Dynamics at Diagnosis and Relapse in Acute Myeloid Leukemia: Influence of Intensity and Type of Treatment. Blood 142(Supp 1):723, 2023.
11. Brown JR, Desikan SP, Nguyen B, Won H, Tantawy SI, McNeely S, Marella N, Ebata K, Woyach JA, Patel K, Tam CS, Eyre TA, Cheah CY, Shah NN, Ghia P, Jurczak W, Balbas M, Nair B, Abada P, Wang C, Wang Y(D), Roeker LE, Gandhi V, Wierda WG. Genomic Evolution and Resistance during Pirtobrutinib Therapy in Covalent BTK-Inhibitor (cBTKi) Pre-Treated Chronic Lymphocytic Leukemia Patients: Updated Analysis from the BRUIN Study. Blood 142(Supp 1):326, 2023. e-Pub 2023.
12. Bataller A, Bazinet A, Borthakur G, Short NJ, Jabbour E, Takahashi K, Daver N, Issa GC, DiNardo CD, Pemmaraju N, Jain N, Montalban-Bravo G, Wierda WG, Ravandi F, Kantarjian HM, Kadia TM. CPX-351 with Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia: Results of a Phase Ib Study. Blood 142(Supp 1):4259, 2023.
13. Bataller A, Kantarjian HM, Kadia TM, Daver N, DiNardo CD, Borthakur G, Short NJ, Yilmaz M, Issa GC, Alvardo Valero, Montalban-Bravo G, Maiti A, Abbas HA, Jabbour E, Wierda WG, Garcia-Manero G, Ravandi F. Poor Outcome of Patients with Acute Myeloid Leukemia in First Relapse Underscores the Need for Effective Initial Treatment. Blood 142(Supp 1):1480, 2023.
14. Veletic I, Harris DM, Rozovski U, Li P, Liu Z, Manshouri T, Bertilaccio MTS, Calin GA, Drula RC, Takahashi K, Furudate K, Muftuoglu M, Hossain A, Ferrajoli A, Burger JA, Jain N, Wierda WG, Verstovsek S, Keating MJ, Estrov Z. CLL Cell-Derived Exosomes Impair Immune Function and Normal Hematopoiesis in CLL. Blood 142(Supp 1):3264, 2023.
15. Kittai AS, Bond DA, Huang Y, Bhat SA, Blyth E, Byrd JC, Chavez JC, Davids MS, Dela Cruz JP, Dowling MR, Duffy C, Ho CI, Jacobson CA, Jaglowski SM, Jain N, Lin KH, McCarthy C, Parry EM, Rai M, Rogers KA, Saha A, Schachter L, Scott H, Senapati J, Shadman M, Siddiqi T, Stephens DM, Vanguru V, Wierda WG, Zulfa O, Woyach JA, Thompson PA. Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter's Transformation: An International Multicenter Retrospective Study. Blood 142(Supp 1):108, 2023.
16. Kim YJ, Li Z, Maiti A, Tanaka T, Uryu H, Furudate K, Hayes K, Daver N, Pemmaraju N, Kadia TM, Ravandi F, Short NJ, Ohanian M, Borthakur G, Jain N, Issa GC, Masarova L, Kornblau SM, Wierda WG, Loghavi S, Wang SA, Garcia-Manero G, Kantarjian H, DiNardo CD, Konopleva MY, Takahashi K. Single-Cell Proteogenomics Analysis of AML Samples Treated with Decitabine and Venetoclax Reveals Divergent Treatment Escape Mechanisms. Blood 142(Supp 1):2931, 2023.
17. Ujjani CS, Gooley T, Siddiqi T, Stephens DM, Broome C, Spurgeon SE, Lai C, Winter A, Pongas G, Greninger A, Hill JA, O'Brien SM, Davis MS, Rogers KA, Danilov A, Quezada G, Zhu H, Sperling A, Sorensen T, Launchbury K, Wierda WG, Shadman M, Thompson PA. Incidence and Management of COVID-19 Infections in Vaccinated Patients with CLL. Blood 142(Supp 1):5149, 2023.
18. Ghia P, Wierda WG, Barr PM, Kipps TJ, Siddiqi T, Allan JN, Hunter Z, Zhou C, Szoke A, Dean JP, Tam CS. Relapse after First-Line Fixed Duration Ibrutinib + Venetoclax: High Response Rates to Ibrutinib Retreatment and Absence of BTK Mutations in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) with up to 5 Years of Follow-up in the Phase 2 Captivate Study. Blood 142(Supp 1):633, 2023.
19. Velarde AM, Saliba RM, Ledesma C, Shpall EJ, Qazilbash MH, Popat UR, Bashir Q, Nieto Y, Marin D, Oran B, Olson AL, Srour SA, Alousi A, Ramdial J, Kebriaei P, Ferrajoli A, Wierda WG, Champlin RE, Hosing C. Allogeneic Transplant for CLL Richter's Transformation: Single Center Retrospective Analysis. Blood 142(Supp 1):7086, 2023.
20. Burger JA, Kim E, Sivina M, Mathew T, Hammond DE, Haddad FG, Ferrajoli A, Wierda WG. Time-Limited Therapy with Zanubrutinib Plus Rituximab in Treatment-Naïve Chronic Lymphocytic Leukemia: Early Results of an Ongoing Phase 2 Trial. Blood 142(Supp 1):6524, 2023.
21. Singh J, Sanchez II JR, Liu C, Slawin B, Jain N, Wierda WG, Zhang K, Niesman M, Blachly JS, Woyach JA, Sampath D. MS-553 Therapy Inhibits BCR Signaling and Increases Survival Dependence on BCL-2 in BTK-Inhibitor Resistant CLL. Blood 142(Supp 1):2283, 2023.
22. Papp E, Ansari S, Wall J, Thompson E, Chen Y, Siddiqi T, Wierda WG, Perna SK, Tuazon SA, Okal A, Peiser L. Undetectable MRD Status in Patients with R/R CLL/SLL with Stable Disease after Lisocabtagene Maraleucel Treatment: Exploratory Analysis of the TRANSCEND CLL 004 Study. Blood 142(Supp 1):3263, 2023.
23. Roeker LE, Woyach JA, Cheah CY, Coombs CC, Shah NN, Wierda WG, Patel M, Tsai DE, Nair B, Wang C, Zhao X, Marella N, Ho C, McNeely S, Brown JR. Fixed-Duration Pirtobrutinib Combined with Venetoclax ± Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia: Updated Results, Including MRD Data, from the BRUIN Phase 1b Study. Blood 142(Supp 1):3269, 2023.
24. Wierda WG, Shah NN, Cheah CY, Lewis D, Hoffmann MS, Coombs CC, Lamanna N, Ma S, Jagadeesh D, Munir T, Wang Y, Eyre TA, Rhodes JM, McKinney M, Lech-Maranda E, Tam CS, Jurczak W, Izutsu K, Alencar AJ, Patel M, Seymour JF, Woyach JA, Roeker LE, Thompson PA, Abada P, Ho C, Marella N, Wang C, Ruppert AS, Nair C, Liu H, Tsai DE, Ghia P. Pirtobrutinib in Richter Transformation: Updated Efficacy and Safety Results with 18-Month Median Survival Follow-up from the Phase 1/2 BRUIN Study. Blood 142(Supp 1):1737, 2023.
25. Senapati J, Kantarjian HM, Jabbour E, Babakhanlou R, Kadia TM, Borthakur G, Konopleva My, Wierda WG, Burger JA, Issa GC, Maiti A, Balkin HS, Kelly M, Garris R, Ferrajoli A, Garcia-Manero G, Alvarado Valero Y, Kebriaei P, Short NJ, Jain N, Ravandi F. Nelarabine (NEL), Pegylated Asparginase (PEG) and Venetoclax (VEN) Incorporated to HCVAD Chemotherapy in the Frontline Treatment of Adult Patients with T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma (T-ALL/T-LBL). Blood 142(Supp 1):963, 2023.
26. Sharman JP, Egyed M, Jurczak W, Skarbnik A, Patel K, Flinn W, Kandar M, Munir T, Walewska R, Hughes M, Fog liatto LM, Herishanu Y, Banerji V, Follows G, Waker PA, Karlsson K, Ghia P, Janssens A, Cymbalista F, Byrd JC, Ferrant E, Ferrajoli A, Wierda WG, Munugalavadla V, Wachira CW, Wun CC, Woyach JA. Acalabrutinib ± Obinutuzumab Vs Obinutuzumab + Chlorambucil in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-up of Elevate-TN. Blood 142(Supp1):563, 2023.
27. Bataller A, Bazinet A, DiNardo CD, Borthakur G, Short NJ, Jabbour E, Takahashi K, Daver N, Issa GC, Pemmaraju N, Jain N, Montalban-Bravo G, <b> Wierda WG</b>, Garcia-Manero G, Ravandi F, Kantarjian HM, Kadia TM. Validation of the Prognostic Risk Signatures for Older Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax. Blood 142(Supp 1):4228, 2023.
28. Maiti A, DiNardo CD, Ohanian M, Daver N, Borthakur G, Chien KS, Issa GC, Takahashi K, Masarova L, Alvarado Valero Y, Jabbour E, Wierda WG, Short NJ, MacFarland M, Pike A, Kadia TM, Ravandi F, Kantarjian HM, Garcia-Manero G, Konopleva MY. Phase II Trial of 10-Day ASTX727 (Decitabine/Cedazuridine) with Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia. Blood 142(Supp 1):4289, 2023.
29. Coombs CC, Woyach JA, Brown JR, Ghia P, Roeker LE, Patel K, Eyre TA, Tam CS, Seymour JF, Shah NN, Flinn IW, Cheah CY, Ma S, Rhodes JM, Izutsu K, Jurczak W, <b>Wierda WG</b>, Loubert A, Payakachat N, Hess LM, Abada P, Lamanna N. Patient-Reported Outcomes (PROs) Among Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Receiving Pirtobrutinib: Analysis from the BRUIN Phase 1/2 Study. Blood 142(Supp 1):6535, 2023.
30. Kittai AS, Huang Y, Miller S, Allan JN, Bhat SA, Bond DA, Brander DM, Byrd JC, Chavez JC, Chong EA, Davids MS, Danilov A, Ding W, Dowling MR, Dvorak-Kornaus KM, Freedman H, Hampel PJ, Ho CI, Hwang SR, Islam P, Jain N, Matasar M, Miller C, Parry EM, Rabe KG, Rai M, Raess P, Roeker LE, Rhodes JM, Rogers KA, Saha A, Schade J, Scott HS, Shadman M, Shouse GP, Skarbnik A, Spurgeon SE, Stephens DM, Thompson MC, Thompson PA, Wang Y, Wierda WG, Yano M, Zulfa O, Woyach JA. Outcomes of Patients with Richter Transformation without Prior Chemoimmunotherapy for CLL/SLL: An International Multicenter Retrospective Study. Blood 142(Supp 1):497, 2023.
31. Danilov A, Tees MT, Patel K, Wierda WG, Patel M, Flinn IW, Latif T, Ai W, Thompson MC, Wang ML, Sun C, Stephens DM, Thirman MJ, Gessner M, Wolff J, Schwab A, Tan M, Chan D, Meredith E, Wiestner A. A First-in-Human Phase 1 Trial of NX-2127, a First-in-Class Bruton's Tyrosine Kinase (BTK) Dual-Targeted Protein Degrader with Immunomodulatory Activity, in Patients with Relapsed/Refractory B Cell Malignancies. Blood 142(Supp 1):4463, 2023. e-Pub 2023.
32. Siddiqi T, Maloney DG, Kenderian SS, Brander DM, Dorritie K, Soumerai J, Riedell PA, Shah NN, Nath R, Fakhri B, Stephens DM, Ma S, Feldman T, Solomon SR, Schuster SJ, Perna SK, Tuazon SA, Ou SS, Papp E, Chen Y, <b>Wierda </b>W. Lisocabtagene Maraleucel (liso-cel) in R/R Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Primary Analysis of the Phase 1/2, Single-Arm, Multicenter TRANSCEND CLL 004 Study. Clin Lymph Myel & Leuk 23(Suppl 1):S320-321, 2023.
33. Haddad F, Jabbour E, Zoghbi M, Short N, Senapati J, Macaron W, Nasnas C, Nasr L, Pemmaraju N, Jain N, Wierda WG, Borthakur G, Montalban-Bravo G, Ravandi F, Garcia-Manero G, Kadia T, Chien K, Thankachan J, Garris R, Kantarjian H. A Phase II Trial of Mini-Hyper-CVD with Venetoclax for Patients with Relapsed/Refractory (R/R) Philadelphia Chromosome (Ph)-Negative Acute Lymphoblastic Leukemia (All). EHA Library, 2023.
34. Siddiqi T, Maloney DG, Kenderian S, Brander DM, Dorritie KA, Soumerai J, Riedell PA, Shah NN, Nath R, Fakhri B, Stephens DM, Ma S, Feldman TA, Solomon SR, Schuster SJ, Perna SK, Ou S, Papp E, Chen Y, Wierda WG. Lisocabtagene maraleucel (liso-cel) in R/R chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Primary analysis of TRANSCEND CLL 004. Journal of Clinical Oncology 41(Supp 16):7501-7501, 2023. e-Pub 2023.
35. Barr PM, Allan JM, Tanya Siddiqi, Wierda WG, Lun Tam CS, Moreno CD, Tedeschi A, Szafer-Glusman E, Zhou C, Abbazio C, Dean JP, Szoke A, Ghia P. Fixed-duration ibrutinib + venetoclax for first-line treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): 4-y follow-up from the FD cohort of the phase 2 CAPTIVATE study. Journal of Clinical Oncology 41(supp 16):7535-7535, 2023. e-Pub 2023.
36. Eyre TA, Thompson P, Wierda WG, Šimkovič M, Grosicki S, Jurczak W, Wang Y, Móciková H, Zinzani PL, Lun Tam CS, Davids MS, Chang AE, Oliveira JM, Lu Y, Leow CC, Roeker LE, Woyach JA. BRUIN CLL-322: A phase 3 open-label, randomized study of fixed duration pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma. Journal of Clinical Oncology 41(Supp 16):TPS7583-TPS7583, 2023. e-Pub 2023.
37. Woyach JA, Coombs CC, Lewis KL, Escalon MP, Ceccarelli M, Bian YF, Wierda WG. BRUIN CLL-314: A phase 3, open-label, randomized study of pirtobrutinib versus ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Journal of Clinical Oncology 41(Supp 16):TPS 7584-TPS7584, 2023. e-Pub 2023.
38. Zoghbi M, Jabbour E, Haddad F, Short NJ, Senapati J, Macaron W, Nasnas CC, Nasr LF, Pemmaraju N, Jain N, Wierda WG, Borthakur G, Bravo GM, Ravandi F, Garcia-Manero G, Kadia TM, Chien KS, Thankachan J, Garris R, Kantarjian HM. Mini-hyper-CVD with venetoclax (Ven) for patients with relapsed/refractory (R/R) Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL): A phase II study. Journal of Clinical Oncology 41(Supp 16):e19039-e19039, 2023. e-Pub 2023.
39. Siddiqi T, Maloney DG, Kenderian S, Brander DM, Dorritie KA, Soumerai J, Riedell PA, Shah NN, Nath R, Fakhri B, Stephens DM, Ma S, Feldman TA, Solomon SR, Schuster SJ, Perna SK, Ou SS, Papp E, Chen Y, Wierda WG. Lisocabtagene maraleucel (liso-cel) in R/R chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Primary analysis of TRANSCEND CLL 004. Journal of Clinnical Oncology 41(Suppl 16):7501-7501, 2023. e-Pub 2023.
40. Woyach JA, Wierda WG, Coombs CC, Lewis KL, Gribben JG, Escalon MP, Ceccarelli M, Wu X, Mato AR. BRUIN CLL-314: A Phase III Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Blood 140(Supplement 1):12427-12428, 2022. e-Pub 2022.
41. Parry EM, Guieze R, Leshchiner I, Johnson C, Tausch E, Parikh SA, Lemvigh CK, Broséus J, Hergalant S, Messer C, Utro F, Levovitz C, Rhrissorrakrai K, Li L, Li S, Fell, Robert A. Redd GG, Lin Z, Knisbacher BA, Schneider C, Fernandes SM, Hess JM, Rassenti LZ, Kipps TJ, Jain N, Wierda WG, Cymbalista F, Feugier P, Kay N, Livak KJ, Danysh BJ, Stewart C, Donna S. Neuberg, Davids MS, Brown JR, Parida L, Stilgenbauer S, Getz G, Wu C. Evolutionary History of Transformation from Chronic Lymphocytic Leukemia to Richter Syndrome. Blood 140(Supplement 1):1530-1533, 2022.
42. Jabbour E, Sasaki K, Issa GC, Haddad F, Garcia-Manero G, Kadia TM, Wierda WG, Yilmaz M, DiNardo CD, Skinner J, Pemmaraju N, Dellasala SE, Pierce SA, Cortes JE, Kantarjian H. Outcome of Third-Line Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in Chronic Phase: A Propensity Score Analysis. Blood 140(Supp. 1):809-811, 2022.
43. Haddad FG, Kantarjian H, Short NJ, Konopleva M, Jain N, Huang X, Ravandi F, Wierda W, Borthakur G, Sasaki K, Issa G, Alvarado Y, Pemmaraju N, Garcia-Manero G, Thankachan J, Garris R, Jabbour E. Updated Results from the Phase II Study of Blinatumomab in Combination With Ponatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Clinical Lymphoma Myeloma and Leukemia 22(Supp. 2):S204, 2022.
44. Jain N, Keating MJ, Thompson PA, Ferrajoli A, Senapati J, Burger JA, Borthakur G, Takahashi K, Estrov ZE, Konopleva M, Sasaki K, Kadia TM, Pemmaraju N, Daver N, Jabbour E, DiNardo CD, Alvarado Y, Yilmaz M, Bose P, Ohanian M, Kanagal-Shamanna R, Patel K, Jorgensen JL, Wang SA, Nassar S, Garg N, Hwang H, Wang X, Cruz N, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda WG. Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 4-Year Follow-up Data. Blood 140(Supp 1):234-237, 2022.
45. Lee HJ, Choi MY, Siddiqi T, Rhodes JM, Wierda WG, Isufi I, Tuscano JM, Lamanna N, Subbiah S, Koff JL, Goldenberg A, GG, Breitmeyer JB, Yazji S, Wang M, Jamieson C, Kipps TJ. Phase 1/2 Study of Zilovertamab and Ibrutinib in Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), or Marginal Zone Lymphoma (MZL). Blood 140(Supp 1):666-568, 2022.
46. Tantawy SI, Aslan B, Chen LS, Iles L, Thompson PA, Jain N, Wierda WG, Gandhi V. Pharmacological Profiling of Cells from Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Pirtobrutinib. Blood 140(Supp 1):501-502, 2022.
47. Lemvigh CK, Parry EM, Deng SL, Dangle NJ, Ruthen N, Knisbacher BA, Broséus J, Hergalant S, Guieze R, Li S, Yin S, Huang T, Livak KJ, Getz G, Neuberg DS, Feugier P, Kharchenko P, Wierda WG , Olsen LR, Jain N, Wu CJ. ZNF683 (Hobit) Marks a CD8+ T Cell Population Associated with Anti-Tumor Immunity Following Anti-PD-1 Therapy for Richter Syndrome. Blood 140(supp1):1807-1808, 2022.
48. Maiti A, DiNardo CD, Ohanian M, Pemmaraju N, Daver N, Borthakur G, Ravandi F, Issa GC, Garcia-Manero G, Jain N, Kadia TM, Masarova L, Wierda WG, Yilmaz M, Alvarado Y, Jabbour E, Short N, Takahashi K, Loghavi S, Patel KP, Montalbano K, Pierce SA, Bivins CA, Mehta RS, Alatrash G, Popat UR, Kebriaei P, Oran B, Shpall EJ, Champlin RE, Kantarjian H, Konopleva M. Long-Term Outcomes of Acute Myeloid Leukemia Following Allogeneic Stem-Cell Transplantation after Decitabine and Venetoclax: Subgroup Analysis of a Phase II Trial. Blood 140(Supp 1):7725-7728, 2022.
49. Mato AR, Wierda WG, Ai WZ, Flinn IW, Tees M, Patel MR, Patel K, O'Brien S, Bond DA, Roeker LE, Siddiqi T, Wang ML, Sun C, Abdel-Wahab O, Schwab A, Tan M, Meredith E, Gessner MA, Kim SY, Wiestner A, Danilov AV. NX-2127-001, a First-in-Human Trial of NX-2127, a Bruton's Tyrosine Kinase-Targeted Protein Degrader, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and B-Cell Malignancies. Blood 140(Supp 1):2329-2332, 2022.
50. Mato AR, Woyach JA, Brown JR, Ghia P, Patel K, Eyre TA, Munir T, Lech-Marańda E, Lamanna N, Tam CS, Seymour JF, Shah NN, Coombs CC, Ujjani CS, Patel MR, Fakhri B, Cheah CY, Alencar AJ, Cohen JB, Gerson JN, Flinn IW, Ma S, Jagadeesh D, Rhodes JM, Hernandez-Ilizaliturri F, Zinzani PL, Balbas M, Nair B, Abada PB, Wang C, Wang D, Tsai DE, Wierda WG, Jurczak W. Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory CLL/SLL: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study. Blood 140(Supp. 1):2316-2320, 2022.
51. Shah NN, Wang ML, Brown JR, Patel K, Woyach JA, Wierda WG, Ujjani CS, Eyre TA, Zinzani PL, Alencar AJ, Gastinne T, Ghia P, Lamanna N, Hoffmann M, Patel MR, Flinn IW, Gerson JN, Ma S, Coombs CC, Cheah CY, Lech-Marańda E, Fakhri B, Kim WS, Barve MA, Cohen JB, Jurczak W, Munir T, Thompson MC, Roeker LE, Bao K, Cangemi NA, Kherani JF, Walgren RA, Han H, Ruppert AS, Mato AR. Safety and Tolerability of Pirtobrutinib Monotherapy in Patients with B-Cell Malignancies Who Were Previously Intolerant to a Covalent BTK Inhibitor: Results from the Phase 1/2 BRUIN Study. Blood 140(Supp 1):4127-4132, 2022.
52. Byrd JC, Woyach JA, Furman RR, Martin P, O'Brien S, Brown JR, Stephens DM, Barrientos JC, Patten PEM, Munir T, Patel K, Butturini A, Borja M, Wang MH, Jain N, Wierda WG. Final Results of the Phase 1/2 Study of Acalabrutinib Monotherapy in Treatment-Naive Chronic Lymphocytic Leukemia with >6 Years of Follow-up. Blood 140(Supp 1):9865-9867, 2022.
53. Singh J, Rohena DD, Liu C, Slawin B, Ravikrishnan J, Jain N, Wierda WG, Zhang K, Niesman M, Woyach JA, Sampath D. MS-553, a Selective PKC-ß Inhibitor Inhibits BCR Signaling and Synergizes with Venetoclax for the Treatment of High Risk CLL. Blood 140(Supp 1):9857-9858, 2022.
54. Allan JN, Siddiqi T, Kipps TJ, Kuss BJ, Badoux XC, Barrientos JC, Tedeschi A, Opat S, Flinn IW, Barca EG, Jacobs R, Szafer-Glusman E, Zhou C, Szoke A, Wierda WG, Ghia P, Tam CS. Treatment Outcomes after Undetectable MRD with First-Line Ibrutinib (Ibr) Plus Venetoclax (Ven): Fixed Duration Treatment (Placebo) Versus Continued Ibr with up to 5 Years Median Follow-up in the CAPTIVATE Study. Blood 140(Supp 1):224-227, 2022.
55. Tam CS, Allan JN, Siddiqi T, Kipps TJ, Jacobs R, Opat S, Barr PM, Tedeschi A, Trentin L, Bannerji R, Jackson S, Kuss BJ, Moreno C, Szafer-Glusman E, Russell K, Zhou C, Ninomoto J, JP Dean, Wierda WG, Ghia P. Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. Blood 139(22):3278-3289, 2022.
56. Siddiqi T, Soumera JDi, Dorritie KA, Stephens DM, Riedell PA, Arnason J, Kipps TJ, Gillenwater HH, Gong L, Yang K, Ogasawara K, Thorpe J, Wierda WG. Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. Blood 139(12):1794-1806, 2022.
57. Rohena DD, Slawin B, Ravikrishnan J, Liu C, Hu W, Zhang P, Thompson PA, Wierda WG, Jain N, Zheng G, Zhou D, Woyach JA, Sampath D. Targeting Venetoclax Resistant CLL Using a Protac-Based BCL-2/BCL-XL Degrader. Blood 140(Supp 1):497-498, 2022.
58. Vaca A, Sivina M, Kim E, Ferrajoli A, Wierda WG, Burger JA. Changes in the T Helper Cell Compartment during Treatment with the BTK Inhibitor Acalabrutinib. Blood 140(Supp 1):9855-9856, 2022.
59. Thompson PA, Keating MJ, Ferrajoli A, Jain N, Peterson CB, Garg N, Ayala A, Hernandez JA, Kadia TM, Bose P, Pemmaraju N, Short N, Wierda WG. Venetoclax Consolidation Achieves Durable Off-Treatment Remissions in Patients with High Risk CLL Who Have Been on Ibrutinib More Than a Year. Blood 140(Supp 1):238-240, 2022.
60. Kim E, Sivina M, Vaca A, Ferrajoli A, Jain N, Thompson PA, Wierda WG, Wodarz D, Chiorazzi N, Burger JA. High Cell Death Rates at Start of Ibrutinib Therapy Predict for Deeper Remissions in Patients with Chronic Lymphocytic Leukemia (CLL). Blood 140(Supp 1):4140-4141, 2022.
61. DiPippo AJ, McGhie A, Lee J, Thompson PA, Jain N, Wierda WG, Kantarjian H, Ferrajoli A. Tolerability of Acalabrutinib after Prior Ibrutinib Treatment in Patients with CLL: Experience of a Tertiary Cancer Care Center. Blood 140(Supp 1):4153-4155, 2022.
62. Desikan SP, Keating MJ, Ferrajoli A, Jain N, Ohanian M, Pemmaraju N, DiNardo CD, Konopleva M, Kadia TM, O'Brien S, Estrov ZE, Thomas DA, Burger JA, Thompson PA, Wierda WG. Early Treatment with Ofatumumab in Patients with High-Risk CLL. Blood 140(Supp n1):9876-9878, 2022.
63. Furman RR, Wierda WG, Schuh A, Patten PE, Chaves JM, Brown JR, Munir T, Martin P, Awan FT, Stephens DM, Ghia P, Barrientos JC, Patel K, Woyach JA, Butturini A, Borja M, Wang MH, O'Brien S, Byrd JC. Phase 1/2 Study of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Results with >4 Years of Follow-up. Blood 140(Supp 1):9873-9875, 2022.
64. Nasnas P, Jabbour E, Short N, Sasaki K, Ravandi F, Jain N, Daver N, Pemmaraju N, Yilmaz M, Kadia TM, Garris R, Garcia-Manero G, DiNardo CD, Konopleva M, Wierda WG, Kwari M, Loiselle C, Milton A, Rivera J, Banks G, Kantarjian H. Frontline Combination of Hyper-CVAD with Ponatinib for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia-6-Year Follow-up Results. Blood 140(Supp 1):3250-3252, 2022.
65. Nasnas P, Jabbour E, Short N, Ravandi F, Huang X, Jain N, Kadia TM, Alvarado Y, Burger JA, Daver N, Borthakur G, DiNardo CD, Konopleva M, Garcia-Manero G, Wierda WG, Jacob J, Deen W, Kwari M, Loiselle C, Roy E, Milton A, Rivera J, Garris R, Kantarjian H. A Phase II Study of Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia: Updated Results and Predictors for Outcomes. Blood 140(Supp1):11679-11682, 2022.
66. Babakhanlou R, Kantarjian H, Jabbour E, Borthakur G, Konopleva M, Wierda WG, Burger JA, Issa GC, Maiti A, Balkin H, Kelly M, Garris R, Ferrajoli A, Garcia-Manero G, Alvarado Y, Short N, Jain N, Ravandi F. Incorporation of Nelarabine (NEL), Pegylated Asparaginase (PEG) and Venetoclax (VEN) in the Frontline Therapy of Adult Patients with T-Acute Lymphoblastic Leukemia/T-Lymphoblastic Lymphoma (T-ALL/LBL). Blood 140(Supp 1):11671-11673, 2022.
67. Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, Leguay T, Bishop MR, Topp MS, Tzachanis D, O'Dwyer KM, Arellano ML, Lin Y, Baer MR, Schiller GJ, Park JH, Subklewe M, Abedi M, Minnema MC, Wierda WG, DeAngelo DJ, Stiff P, Jeyakumar D, Dong J, Adhikary S, Zhou L, Schuberth PC, Faghmous I, Masouleh BK, Houot R. Updated Outcomes from the Historical Control Study SCHOLAR-3 Contextualizing ZUMA-3 Results of Brexucabtagene Autoleucel (KTE-X19) in Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL). Blood 140(Supp 1):3158-3161, 2022.
68. Macaron W, Kantarjian HM, Short NJ, Ravandi F, Jain N, Kadia TM, Haddad F, Valero YA, Daver NG, Borthakur G, DiNardo CD, Konopleva M, Wierda WG, Jacob J, Roy E, Loiselle C, Milton A, Rivera J, Garris R, Jabbour E. Updated results from a phase II study of mini-hyper-CVD (mini-HCVD) plus inotuzumab ozogamicin (INO), with or without blinatumomab (Blina), in older adults with newly diagnosed Philadelphia chromosome (Ph)-negative B-cell acute lymphoblastic leukemia (ALL). J Clin Oncol 40(Supplement 1), 2022.
69. Wierda WG, Barr PM, Siddiqi T, Allan JN, Kipps TJ, Trentin L, Jacobs R, Jackson S, Tedeschi A, Opat S, Bannerji R, Kuss BJ, Moreno C, Croner LJ, Szafer-Glusman E, Zhou C, Szoke A, Dean JP, Ghia P, Tam CSL. Fixed-duration (FD) ibrutinib (I) + venetoclax (V) for first-line (1L) treatment (tx) of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Three-year follow-up from the FD cohort of the phase 2 CAPTIVATE study. J Clin Oncol 40(Supplement 1), 2022.
70. Lee HJ, Choi MY, Siddiqi T, Rhodes JM, Wierda WG, Isufi I, Tuscano JM, Lamanna N, Subbiah S, Koff JL, Leslie LA, Goldenberg A, Chung GG, Yazji S, Wang Y, Breitmeyer JB, Wang M, Jamieson C, Kipps TJ. Phase 1/2 study of zilovertamab and ibrutinib in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL). J Clin Oncol 40(Supplement 1), 2022.
71. Mato A, Danilov AV, Patel MR, Tees MT, Flinn IW, Ai WZ, Patel K, Wang M, O'Brien SM, Nandakumar S, Tan M, Meredith E, Gessner M, Kim SY, Wiestner A, Wierda WG. A first-in-human phase 1 trial of NX-2127, a first-in-class oral BTK degrader with IMiD-like activity, in patients with relapsed and refractory B-cell malignancies. J Clin Oncol 40(Supplement 1), 2022.
72. Siddiqi T, Soumerai JD, Dorritie KA, Stephens DM , Riedell PA, Arnason J, Kipps TJ, Gillenwater HH, Gong L, Yang L, Ogasawara K, Thorpe J, <b>Wierda WG</b>. Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. Blood 139(12):1794-1806, 2022. e-Pub 2022.
73. Short NJ, Kantarjian HM, Konopleva M, Jain N, Huang X, Ravandi F, Wierda WG, Borthakur G, Sasaki K, Issa GC, Alvarado Y, Pemmaraju N, Garcia-Manero G, Thankachan J, Garris R, Jabbour E. Combination of ponatinib and blinatumomab in Philadelphia chromosome-positive acute lymphoblastic leukemia: Early results from a phase II study. Journal of Clinical Oncology 39(Supp 15):7001-7001, 2021. e-Pub 2021.
74. Ghia P, Allan JN, Siddiqi T, Kipps TJ, Jacobs R, Opat S, Barr PM, Tedeschi A, Trentin L, Bannerji R, Jackson S, Kuss B, Moreno C, Szafer-Glusman E, Russell K, Zhou C, Ninomoto JS, Dean JP, Wierda WG||B, Si Lun Tam C. Fixed-duration (FD) first-line treatment (tx) with ibrutinib (I) plus venetoclax (V) for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Primary analysis of the FD cohort of the phase 2 captivate study. Journal of Clinical Oncology 39(Suppl 15), 2021. e-Pub 2021.
75. Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Kamdar MK, Munir T, Corbett G, Fogliatto LM, Herishanu Y, Banerji V, Coutre SE, Walker P, Karlsson K, Ghia P, Janssens A, Wierda WG, Patel P, Wang MH, Byrd JC. Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in treatment-naïve chronic lymphocytic leukemia: Elevate-TN four-year follow up. Journal Of Clinical Oncology 39(Suppl 15):7509-7509, 2021. e-Pub 2021.
76. Lee HJ, Choi MY, Siddiqi T, Barrientos JC, <b>Wierda WG</b>, Isufi I, Tuscano JM, Lamanna N, Subbiah S, Koff JL, Leslie LA, Goldenberg A, Chung GG, Breitmeyer JB, Hsu FJ, Wang M, Jamieson C, Kipps TJ. Phase 1/2 study of cirmtuzumab and ibrutinib in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL. Journal of Clinical Oncology 39(Suppl 15):7556-7556, 2021. e-Pub 2021.
77. Jain N, Keating MJ, Thompson PA, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Estrov Z, Sasaki K, Kadia TM, Konopleva M, Alvarado Y, Yilmaz M, DiNardo CD, Bose P, Ohanian M, Pemmaraju N, Jabbour EJ, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen JL, Wang SA, Garg N, Wang X, Wei C, Cruz N, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda WG. Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL): Focus on Long-Term MRD Results. Blood 138(Supplement 1), 2021.
78. Ghia P, Allan JN, Siddiqi T, Kipps TJ, Kuss BJ, Opat S, Flinn IW, Badoux XC, Tedeschi A, Gonzalez-Barca E, Pagel JM, Jacobs R, Barrientos J, Szafer-Glusman E, Zhou C, Ninomoto J, Dean JP, Tam CS, Wierda WG. First-Line Treatment with Ibrutinib (Ibr) Plus Venetoclax (Ven) for Chronic Lymphocytic Leukemia (CLL): 2-Year Post-Randomization Disease-Free Survival (DFS) Results from Minimal Residual Disease (MRD) Cohort of the Phase 2 Captivate Study. Blood 138(Supplement 1):68, 2021.
79. Lee LW, Ching T, Howie B, Patel KP, Thompson PA, Jain N, Ferrajoli A, Estrov ZE, Burger JA, Keating MJ, Kanagal-Shamanna R, Wierda WG, Kirsch LR. Assessment of Immunoglobulin Heavy Chain Variable Region (IGHV) Mutation Status with a Next Generation Sequencing (NGS) Immunosequencing Assay for Measurable Residual Disease (MRD). Blood 138(Supplement 1):4676, 2021.
80. Griffen TL, Hoff FW, Qiu Y, Lillard JW, Ferrajoli A, Thompson PA, Toro E, Ruiz K, Burger JA, Wierda WG, Kornblau SM. Proteomic Profiling Based Classification of CLL Provides Prognostication for Modern Therapy and Identifies Novel Therapeutic Targets. Blood 138(Supplement 1):1538, 2021.
81. Venugopal S, Kantarjian H, Short NJ, Thompson PA, Pemmaraju N, Jain N, Wierda WG, Borthakur G, Montalban-Bravo G, Ravandi F, Garcia-Manero G, Kadia TM, Ohanian M, Chien KS, Thankachen J, Nwakanme B, Garris R, Jabbour EJ. A Phase II Study of Mini-Hyper-CVD Plus Venetoclax in Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia. Blood 138(Supplement 1):1239, 2021.
82. Kim K, Kantarjian H, Borthakur G, Takahashi K, Short NJ, DiNardo CD, Jabbour EJ, Chien KS, Daver N, Pemmaraju N, Jain N, Adewale L, Montalban-Bravo G, Wierda WG, Verstovsek S, Konopleva M, Ravandi F, Kadia TM. A Phase II Study of CPX-351 Plus Venetoclax in Patients with Relapsed/Refractory (R/R) or Newly Diagnosed Acute Myeloid Leukemia (AML). Blood 138(Supplement 1):1275, 2021.
83. Vaca A, Ioannou N, Sivina M, Vlachonikola E, Clise-Dwyer K, Kim E, Li D, Ma Q, Ferrajoli A, Estrov ZE, Wierda WG, Patten PEM, Ramsey AG, Burger JA. Expansion of T Follicular Helper Cells in NLC Co-Cultures Reinforces the Concept of Co-Evolution of CLL and Supportive T Helper Cell Clones. Blood 138(Supplement 1):3716, 2021.
84. Thompson PA, Wang Y, Keating MJ, Ferrajoli A, Jain N, Peterson CB, Garg N, Wei C, Ayala A, Kadia TM, Bose P, Pemmaraju N, Short NJ, Wierda WG. Venetoclax Consolidation in Patients with High-Risk CLL Who Have Been on Ibrutinib More Than a Year Achieves a High Rate of Undetectable Minimal Residual Disease. Blood 138(Supplement 1):3723, 2021.
85. Sivina M, Kim E, Wierda WG, Ferrajoli A, Jain N, Thompson PA, Estrov ZE, Kantarjian H, Keating MJ, Burger JA. Long-Term Outcome of Treatment-Naive and Relapsed/Refractory Patients with CLL and TP53 Aberrations Treated with Ibrutinib, with or without Rituximab. Blood 138(Supplement 1):3734, 2021.
86. Mato AR, Wierda WG, Pagel JM, Davids MS, Zinzani PL, Lu Y, Liu H, Shahda S, Leow CC, Tam CS, Woyach JA, Eyre TA. BRUIN CLL-322: A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Trial in Progress). Blood 138(Supplement 1):3742, 2021.
87. Lee HJ, Choi M, Siddiqi T, Barrientos J, Wierda WG, Isufi I, Tuscano J, Lamanna N, Subbiah S, Koff JL, Leslie LA, Goldenberg A, Chung GG, Breitmeyer JB, Yazji S, Wang Y, Wang M, Jamieson C, Kipps TJ. Phase 1b/2 Study of Cirmtuzumab and Ibrutinib in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL). Blood 138(Supplement 1):3534, 2021.
88. Jain N, Ferrajoli A, Yilmaz M, Thompson PA, Konopleva M, Green MR, Sampath D, Neelapu SS, Takahashi K, Masarova L, Burger JA, Kanagal-Shamanna R, Khoury JD, Garg N, Su X, Wang X, Patel H, Ayala A, Kantarjian H, Keating MJ, Wierda WG. Venetoclax, Obinutuzumab and Atezolizumab (PD-L1 Checkpoint Inhibitor) for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL). Blood 138(Supplement 1):2626, 2021.
89. Rohena DD, Ravikrishnan J, Liu C, Zheng G, Zhou D, Zhang P, Wierda WG, Jain N, Woyach JA, Sampath D. Targeting Venetoclax-Resistant CLL By Bcl-XL Degradation. Blood 138(Supplement 1):2252, 2021.
90. Patel K, Michot J-M, Chanan-Khan A, Ghesquieres H, Bouabdallah K, Byrd JC, Cartron G, Portell CA, Soth M, Tilly H, Wierda WG, McGovern P, Johnson C, Garcha R, Ribrag V, Brisou G, Liebowitz D, Phillips T. Safety and Anti-Tumor Activity of Plamotamab (XmAB13676), an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Subjects with relapsed/Refractory Non-Hodgkin's Lymphoma. Blood 138(Supplement 1):2494, 2021.
91. Jain N, Ferrajoli A, Thompson PA, Konopleva M, Green MR, Sampath D, Neelapu SS, Takahashi K, Strati P, Burger JA, Kanagal-Shamanna R, Khoury JD, Garg N, Su X, Wang X, Patel H, Ayala A, Kantarjian H, Keating MJ, Wierda WG. Venetoclax, Obinutuzumab and Atezolizumab (PD-L1 Checkpoint Inhibitor) for Treatment for Patients with Richter Transformation. Blood 138(Supplement 1):1550, 2021.
92. Kadia TM, Ravandi F, Borthakur G, Yilmaz M, Montalban-Bravo G, Adewale L, Pierce SA, Jain N, Ferrajoli A, Wierda WG, Kantarjian H. A Phase Ib Pilot Study of Itacitinib Combined with Alemtuzumab in Patients with T-Cell Prolymphocytic Leukemia (T-PLL). Blood 138(Supplement 1):1375, 2021.
93. Maiti A, DiNardo CD, Rausch CR, Pemmaraju N, Garcia-Manero G, Ohanian M, Daver N, Issa GC, Borthakur G, Ravandi F, Alvarado Y, Kadia TM, Short NJ, Jabbour EJ, Montalban-Bravo G, Jain N, Kornblau SM, Masarova L, Wierda WG, Sasaki K, Takahashi K, Yilmaz M, Burger JA, Estrov ZE, Verstovsek S, Andreeff M, Bose P, Ferrajoli A, Thompson PA, Montalbano K, Vaughan K, Bivins CA, Pierce SA, Qiao W, Ning J, Welch J, Kantarjian H, Konopleva M. Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia and Myelodysplastic Syndrome: Updated Results of a Phase II Trial. Blood 138(Supplement 1):1270, 2021.
94. Maiti A, DiNardo CD, Rausch CR, Pemmaraju N, Garcia-Manero G, Ohanian M, Daver N, Issa GC, Borthakur G, Ravandi F, Alvarado Y, Kadia TM, Jabbour EJ, Short NJ, Montalban-Bravo G, Jain N, Kornblau SM, Masarova L, Wierda WG, Sasaki K, Takahashi K, Yilmaz M, Burger JA, Estrov ZE, Verstovsek S, Andreeff M, Bose P, Ferrajoli A, Thompson PA, Montalbano K, Vaughan K, Bivins CA, Pierce SA, Qiao W, Ning J, Welch JS, Kantarjian H, Konopleva M. Phase II Trial of Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Outcomes in Genomic Subgroups. Blood 138(Supplement 1):694, 2021.
95. Short NJ, Kantarjian HM, Ravandi F, Huang X, Jain N, Kadia TM, Khoury JD, Jorgensen JL, Wang SA, Alvarado Y, Burger JA, Daver N, Borthakur G, DiNardo CD, Konopleva M, Pemmaraju N, Garcia-Manero G, Wierda WG, Kornblau SM, Jacob J, Kwari M, Rausch CR, Loiselle C, Milton A, Rivera J, Garris R, O'Brien SM, Jabbour E. Updated Results from a Phase II Study of Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. Blood 138(Supplement 1):3400, 2021.
96. Mato AR, Pagel JM, Coombs CC, Shah NN, Lamanna N, Munir T, Lech-Marańda E, Eyre TA, Woyach JA, Wierda WG, Cheah CY, Cohen JB, Roeker LE, Patel MR, Fakhri B, Barve MA, Tam CS, Lewis DJ, Gerson JN, Alencar AJ, Ujjani CS, Flinn IW, Sundaram S, Ma S, Jagadeesh D, Rhodes JM, Taylor J, Abdel-Wahab O, Ghia P, Schuster SJ, Wang D, Nair B, Zhu E, Tsai D, Davids MS, Brown JR, Jurczak W. Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN Study. Blood 138(Supplement 1):391, 2021.
97. Short NJ, Kantarjian H, Konopleva M, Desikan SPP, Jain N, Ravandi F, Huang X, Wierda WG, Borthakur G, Sasaki K, Issa GC, Alvarado Y, Pemmaraju N, Garcia-Manero G, DiNardo CD, Thankachan J, Delumpa R, Milton A, Rivera J, Waller L, Garris R, Jabbour EJ. Updated Results of a Phase II Study of Ponatinib and Blinatumomab for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Blood 138(Supplement 1):2298, 2021.
98. Sakurai K, Kantarjian HM, Sasaki K, Jabbour E, Ravandi F, Konopleva M, Borthakur G, Wierda WG, Daver NG, Takahashi K, Naqvi K, Dinardo CD, Bravo GM, Issa GC, Jain P, Pierce SA, Soltysiak KA, Garcia-Manero G, Tingen MS, Cortes JE. Geographic disparity of outcome in patients with cancer over decades: The surveillance, epidemiology, and end results. Journal of Clinical Oncology 38(Suppl 15):1574-1574, 2020. e-Pub 2020.
99. Byrd JC, Woyach JA, Furman RR, Martin P, O'Brien SM, Brown JR, Stephens DM, Barrientos JC, Devereux S, Hillmen P, Pagel JM, Hamdy AM, Izumi R, Patel P, Wang MH, Jain N, Wierda WG. Acalabrutinib in treatment-naïve chronic lymphocytic leukemia: Mature results from phase II study demonstrating durable remissions and long-term tolerability. Journal of Clinical Oncology 38(Suppl 15):8024-2024, 2020. e-Pub 2020.
100. Lee HJ, Choi MY, Siddiqi Y, Wierda, Barrientos JC, Lamanna N, Goldenberg A, Isufi I, Tuscano JM, Subbiah S, Weihe EK, Ianopulos X, Breitmeyer JB, Hsu FJ, Wang M, Jamieson CH, Kipps TJ. Clinical activity of cirmtuzumab, an anti-ROR1 antibody, in combination with ibrutinib: Interim results of a phase Ib/II study in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL). Journal of Clinical Oncology 38(Suppl 15):8036-8036, 2020. e-Pub 2020.
101. Guerra V, Ologun GO, Haydu LE, Zhi-Yun Keung E, Burton EM, Tawbi HA, Wierda WG, Davies MA, Wargo JA, Ferrajoli A. Efficacy of immune checkpoint inhibitors for the treatment of metastatic melanoma (MM) in patients with concurrent chronic lymphocytic leukemia (CLL). Journal of Clinical Oncology 38(Suppl 15):e22044, 2020. e-Pub 2020.
102. Chen Q, Ayer T, Wierda WG, Flowers CR, O'Brien SM, Keating MJ, Kantarjian HM, Chhatwal J. Study of Low Dose Ibrutinib Use in a Community-Based Oncology Practice. Blood 136(Supplement 1), 2020.
103. Wierda WG, Tam CS, Allan JN, Siddiqi T, Kipps TJ, Opat S, Tedeschi A, Badoux XC, Kuss BJ, Jackson S, Moreno C, Jacobs R, Pagel JM, Flinn IW, Zhou C, Szafer-Glusman E, Ninomoto J, Dean JP, James DF, Ghia P. Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): 1-Year Disease-Free Survival (DFS) Results From the MRD Cohort of the Phase 2 CAPTIVATE Study. Blood 136(Supplement 1), 2020.
104. Lachowiez C, Konopleva M, Kadia TM, Daver N, Loghavi S, Wang SA, Adeoti M, Pierce SA, Takahashi K, Short NJ, Sasaki K, Borthakur G, Issa GC, Wierda WG, Pemmaraju N, Montalban Bravo G, Ferrajoli A, Jain N, Masarova L, Yilmaz M, Jabbour E, Garcia-Manero G, Kornblau SM, Ravandi F, Kantarjian HM, Dinardo CD. Interim Analysis of the Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML. Blood 136(Supplement 1), 2020.
105. Sasaki K, Jabbour E, Issa GC, Garcia-Manero G, Kadia TM, Wierda WG, Yilmaz M, DiNardo CD, Skinner J, Khouri M, Pemmaraju N, Nasnas P, Pierce SA, Cortes JE, Kantarjian HM. Outcomes of Patients with Chronic Myeloid Leukemia Treated with Third-Line Tyrosine Kinase Inhibitors. Blood 136(Supplement 1), 2020.
106. Lee HJ, Choi MY, Siddiqi T, Wierda WG, Barrientos JC, Lamanna N, Goldenberg A, Isufi I, Tuscano J, Subbiah S,Koff JL, Leslie LA, Chung GG, Weihe EK, Ianopulos X, Breitmeyer JB, Hsu FJ, Wang M, Jamieson C, Kipps TJ. Cirmtuzumab, an Anti-ROR1 Antibody, in Combination with Ibrutinib: Clinical Activity in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL) from a Phase 1/2 Study. Blood 136(Supplement 1), 2020.
107. Short NJ, Kantarjian HM, Ravandi F, Huang X, Jain N, Kadia TM, Khoury JD, Jorgensen JL, Wang SA, Alvarado Y, Burger JA, Daver N, Borthakur G, DiNardo CD, Konopleva M, Pemmaraju N, Garcia-Manero G, Wierda WG, Kornblau SM, Jacob JJ, Rostykus M, Kwari M, Rausch CR, Loiselle C, Milton A, Rivera J, Garris R, O'Brien SM, Jabbour E. Reduced-Intensity Chemotherapy with Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study. Blood 136(Supplement 1), 2020.
108. Maiti A, Jabbour E, Jain N, Borthakur G, Kadia TM, Burger JA, Wierda WG, Konopleva M, Alvarado Y, Short NJ, Faderl S, O'Brien SM, Ferrajoli A, Kornblau SM, Daver N, Pemmaraju N, Bose P, Thompson PA, Khoury JD, Balkin H, Kelly M, Azzawi H, Garris R, Garcia-Manero G, Kantarjian HM, Ravandi F. Frontline HCVAD with Nelarabine and Peg-Asparaginase in T-Acute Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LBL): Updated Results of a Phase II Trial. Blood 136(Supplement 1), 2020.
109. Mato AR, Pagel JM, Coombs CC, Shah NN, Lamanna N, Lech-Marańda E, Eyre TA, Woyach JA, Wierda WG, Cheah CY, Roeker LE, Patel MR, Fakhri B, Barve M, Tam CS, Lewis DJ, Gerson JN, Alencar AJ, Taylor J, Abdel-Wahab O, Ghia P, Schuster SJ, Chen J, Nair B, Tsai D, Ku NC, Davids MS, Brown JR, Jurczak W. LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study. Blood 136(Supplement 1), 2020.
110. Wierda WG, Dorritie KA, Munoz J, Stephens DM, Solomon SR, Gillenwater HH, Gong L, Yang L, Ogasawara K, Thorpe J, Siddiqi T. Transcend CLL 004: Phase 1 Cohort of Lisocabtagene Maraleucel (liso-cel) in Combination with Ibrutinib for Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). Blood 136(Supplement 1), 2020.
111. Siddiqi T, Soumerai JD, Dorritie KA, Stephens DM, Riedell PA, Arnason JE, Kipps TJ, Gillenwater HH, Gong L, Yang L, Ogasawara K, Wierda WG. Updated Follow-up of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated with Lisocabtagene Maraleucel in the Phase 1 Monotherapy Cohort of Transcend CLL 004, Including High-Risk and Ibrutinib-Treated Patients. Blood 136(Supplement 1), 2020.
112. El Elhussein S, Medeiros LJ, Lyapichev KA, Gruschkus SK, Wei P, Schlette E, Fiskus W, Kanagal-Shamanna R, Loghavi S, Yang H, Li S, Xu J, Tang Z, Thakral B, Jain N, Wierda WG, Patel K, Bhalla KN, Khoury JD. Immune Evasion Phenotype Is Common in Richter Transformation Diffuse Large B-Cell Lymphoma and Correlates with CD30 Expression. Blood 136(Supplement 1), 2020.
113. Rafei H, Kantarjian HM, Sasaki K, Short NJ, Ravandi F, Huang X, Khoury JD, Wang SA, Jorgensen JL, Khouri IF, Kebriaei P, Champlin RE, Jain N, Dabaja BS, Issa GC, Pemmaraju N, Kadia TM, Paul S, Jammal N, Garcia-Manero G, Wierda WG, DiNardo CD, Daver N, Montalban-Bravo G, Khouri R, Nasnas P, Thompson PA, Jacob J, Rostykus M, Garris R, Konopleva M, O'Brien SM, Jabbour E. Role of Allogeneic Stem Cell Transplant (ASCT) in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab (Blina): Results from a Phase 2 Study. Blood 136(Supplement 1):39-41, 2020.
114. Rafei H, Kantarjian HM, Sasaki K, Short NJ, Ravandi F, Huang X, Khoury JD, Wang SA, Jorgensen JL, Yin C, Khouri IF, Kebriaei P, Jain N, Takahashi K, Dabaja BS, Verstovsek S, Kadia TM, Paul S, Rausch CR, Garcia-Manero G, Wierda WG, DiNardo CD, Daver N, Montalban-Bravo G, Yilmaz M, Nasnas P, Khouri R, Kwari M, Jacob J, Rostykus M, Garris R, Konopleva M, O'Brien SM, Jabbour E. Impact of Cytogenetic Abnormalities (CA) on Outcome of Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study. Blood 136(Supplement 1):45-47, 2020.
115. Sasaki K, Kantarjian HM, Issa GC, Garcia-Manero G, Kadia TM, Wierda WG, Yilmaz M, DiNardo CD, Skinner J, Khouri R, Pemmaraju N, Nasnas P, Dellasala SE, Pierce SA, Cortes JE, Jabbour E. Impact of Molecular Response at Specific Timepoints in Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Second Generation Tyrosine Kinase Inhibitors. Blood 136(Supplement 1):42-44, 2020.
116. Cherng HJ, Jammal N, Paul S, Wang X, Sasaki K, Thompson PA, Burger JA, Ferrajoli A, Estrov ZE, O'Brien SM, Keating MJ, Wierda WG, Jain N. Examination of Clinical and Molecular Characteristics and Treatment Patterns of Adolescent and Young Adult (AYA) Patients with Chronic Lymphocytic Leukemia. Blood 136(Supplement 1):5-6, 2020.
117. Jones J, George BS, Peterson CB, Ha TT, Burger JA, Jain N, Keating MJ, Wierda WG, Durand J-B, Ferrajoli A. Hypertension, Cardiovascular and Renal Complications Observed in Patients with Chronic Lymphocytic Leukemia Receiving Long-Term Therapy with Ibrutinib. Blood 136(Supplement 1):27-28, 2020.
118. Thompson PA, Ferrajoli A, Jain N, Wang Y, Peterson CB, Garg N, Wei C, Ayala A, Kadia TM, Bose P, Pemmaraju N, Short NJ, Keating MJ, Wierda WG. The Addition of Venetoclax to Ibrutinib Achieves a High Rate of Undetectable Minimal Residual Disease in Patients with High-Risk CLL. Blood 136(Supplement 1):28-29, 2020.
119. Seymour JF, Gribben JG, Davids MS, Mato A, Sharman JP, Cyr A, Bartkus C, Pena G, Boyer M, Sharmokh S, Rosenberg TS, Wierda WG. Assessment of Tumor Lysis Syndrome in Patients with Chronic Lymphocytic Leukemia Treated with Venetoclax in the Clinical Trial and Post-Marketing. Blood 136(Supplement 1):37-38, 2020.
120. Sivina M, Jain N, Kim E, Kadia TM, Estrov ZE, Ohanian M, Andreeff M, Thomas M, Thompson PA, Kantarjian HM, Keating MJ, O'Brien SM, Wierda WG, Ferrajoli A, Burger JA. Ibrutinib Induces Durable Remissions in Treatment-Naive CLL Patients with 17p Deletion/TP53 Mutations: Five Year Follow-up from a Phase 2 Study. Blood 136(Supplement 1):22-23, 2020.
121. Parry EM, Guieze R, Leshchiner I, Rosebrock D, Persaud B, Lemvigh CK, Tausch E, Davids MS, Bloehdorn J, Schneider C, Elagina L, Martinez AZ, Taylor-Weiner A, Jain N, Wierda WG, Rassenti LZ, Kipps TJ, Broseus J, Cymbalista F, Kay NE, Livak KJ, Li S, Huang T, Purroy N, Anandappa AJ, Fernandes SM, Utro F, Rhrissorrakrai K, Levovitz C, Danysh BP, Slowik K, Parikh SA, Brown JR, Parida L, Neuberg DS, Stilgenbauer S, Getz G, Wu CJ. Genetic Determinants and Evolutionary History of Richter's Syndrome. Blood 136(Supplement 1):47-48, 2020.
122. Sharman JP, Banerji V, Fogliatto LM, Herishanu Y, Munir T, Walewska R, Follows G, Karlsson K, Ghia P, Corbett G, Walker P, Egyed M, Jurczak W, Salles G, Janssens A, Cymbalista F, Wierda WG, Coutre S, Pagel JM, Skarbnik A, Kamdar M, Woyach J, Izumi R, Munugalavadla V, Patel P, MH Wang, , Wong S, Byrd JC. ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL). Blood 134(Supplement 1):31, 2019.
123. Short NJ, Kantarjian HM, Ravandi F, Huang X, Jain N, Sasaki K, Khouri R , Daver NG, Pemmaraju N, Khoury JD, Jorgensen JL, , Alvarado Y, Konopleva MY, Garcia-Manero G, Kadia TM, Yilmaz ME, Borthakur GM, Burger JA, Kornblau SM, Wierda WG, DiNardo CD, Ferrajoli A, Jacob J, Rostykus M, Garris R, Ward M, Huang B, Encarnacion C, Loiselle C, O'Brien SM, Jabbour E. Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia. Blood 134(Supplement 1):823, 2019.
124. William G. Wierda, MD PhD , Seung Tae Lee, MD PhD , Rong Chen, PhD , Daniella Zheleva, PhD , David Blake, PhD , Judy H Chiao, MD , William Plunkett, PhD. A Phase I Study Combining CDK2/9 Inhibitor CYC065 with Venetoclax, a BCL2 Inhibitor, to Treat Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL). Blood 134(Supplement 1):1761, 2019.
125. Koji Sasaki, MD , Hagop M. Kantarjian, MD , Elias Jabbour, MD , Farhad Ravandi, MD , Marina Y Konopleva, MD PhD , Gautam M. Borthakur, MD , <b>William G. Wierda, MD PhD</b> , Naval G. Daver, MD , Koichi Takahashi, MD , Kiran Naqvi, MDMPH , Courtney D. DiNardo, MDMSc , Guillermo Montalban Bravo, MD , Rashmi Kanagal-Shamanna, MD , Naveen Pemmaraju, MD , Ghayas C. Issa, MD , Preetesh Jain, MBBS,MDDM,PhD , Jeffrey Skinner, MHA , Mary B. Rios, RN , Sherry A. Pierce, BSN, BA , Kelly Soltysiak, PhD , Junya Sato , Guillermo Garcia-Manero, MD , Jorge E. Cortes, MD. The Impact of Treatment Recommendation By Leukemia Artificial Intelligence Program (LEAP) on Survival in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP). Blood 134(Supplement 1):1642, 2019.
126. Jeff P. Sharman, MD, Versha Banerji, MD, Laura Maria Fogliatto, MD PhD, Yair Herishanu, MD, Talha Munir, MD, Renata Walewska, George Follows, Karin Karlsson, MD, Paolo Ghia, MD PhD, Gillian Corbett, Patricia Walker, MBBS, Miklos Egyed, Wojciech Jurczak, MD PhD, Gilles Salles, MD PhD, Ann Janssens, Florence Cymbalista, MD PhD, William Wierda, MD,PhD, Steven Coutre, MD, John M. Pagel, MD PhD DSc, Alan Skarbnik, MD, Manali Kamdar, MD, Jennifer Woyach, MD, Raquel Izumi, PhD, Veerendra Munugalavadla, PhD, Priti Patel, MD, Min Hui Wang, PhD, Sofia Wong, John C. Byrd, MD. Expansion of T Helper Cell Subsets in Chronic Lymphocytic Leukemia Cell Co-Cultures with Nurselike Cells. Blood 134(Supplement 1):1746, 2019.
127. Michael Y. Choi, MD , Emanuela M. Ghia, PhD , Tanya Siddiqi, MD , William G. Wierda, MD PhD , Hun Ju Lee , Jacqueline C. Barrientos, MD MS , Nicole Lamanna, MD , Alec Goldenberg , Dimitrios Tzachanis, MD PhD , Erin G. Reid, MD MS , Elizabeth K Weihe, MD , Laura Z. Rassenti, PhD , Iris Isufi, MD , Stewart Bieler, BA , Xen Ianopulos, MD PhD , James B. Breitmeyer, MD PhD , Catriona Jamieson, MD PhD , Thomas J. Kipps, MD PhD. Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for CLL and MCL. Blood 134(Supplement 1):1755, 2019.
128. Anthony R. Mato, MDMSCE , Kavita Sail, PhD , Maryam Sarraf Yazdy, MD , Brian T. Hill, MD , Mazyar Shadman, MD MPH , Beenish S Manzoor, PhD , Hande H. Tuncer, MD , John N. Allan, MD , Chaitra S. Ujjani, MD , Simon Sharmokh, MPH, PharmD , Daniel Dingfeng Jiang, MD PhD , German Pena, MD , Thomas Marshall, PharmD, MS , Jacqueline Nielsen, PhD , Paul M. Barr, MD , Jennifer R. Brown, MD PhD , Anna Schuh, PhD , Toby A. Eyre, MD , William G. Wierda, MD PhD , Alan Skarbnik, MD , Lindsey E. Roeker, MD , Rajat Bannerji, MD PhD , James M. Pauff, MD PhD , Stephen J. Schuster, MD , George A Follows, MD PhD , Bruce D. Cheson, MD , Barbara F. Eichhorst, MD , Danielle M. Brander, MD , Irina Pivneva, PhD , Nicole Lamanna, MD. Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel Therapies. Blood 134(Supplement 1):1756, 2019.
129. Nitin Jain, MD , Michael J Keating, MBBS , Philip A. Thompson, MBBS , Alessandra Ferrajoli, MD , Jan A. Burger, MD PhD , Gautam M. Borthakur, MD , Koichi Takahashi, MD , Zeev E. Estrov, MD , Nathan H. Fowler, MD , Tapan M. Kadia, MD , Marina Y Konopleva, MD PhD , Yesid Alvarado, MD , Musa Yilmaz, MD , Courtney D. DiNardo, MDMSc , Prithviraj Bose, MD , Maro Ohanian, DO , Naveen Pemmaraju, MD , Elias Jabbour, MD , Koji Sasaki, MD , Rashmi Kanagal-Shamanna, MD , Keyur Patel, MD PhD , Jeffrey L. Jorgensen, MD PhD , Sa A Wang, MD , Naveen Garg, MD , Xuemei Wang, MS , Katrina Sondermann, BA , Nichole Cruz, RN , Chongjuan Wei, PhD , Ana Ayala, RN , William Plunkett, PhD , Hagop M. Kantarjian, MD , Varsha Gandhi, PhD , William G. Wierda, MD PhD. Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL). Blood 134(Supplement 1):34, 2019.
130. Tanya Siddiqi, MD , Jacob D. Soumerai, MD , Kathleen A. Dorritie, MD , Deborah M. Stephens, DO , Peter A. Riedell, MD , Jon E. Arnason, MD , Thomas J. Kipps, MD PhD , Heidi H. Gillenwater, MD , Lucy Gong, PharmD , Jason A. Dubovsky, PhD , Julie Rytlewski, PhD , Lin Yang , William G. Wierda, MD PhD. Rapid Undetectable MRD (uMRD) Responses in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed CAR T Cell Product: Updated Results from Transcend CLL 004, a Phase 1/2 Study Including Patients with High-Risk Disease Previously Treated with Ibrutinib. Blood 134(Supplement 1):503, 2019.
131. Vivian M. Liu, MD , Romain Guièze, MD , Daniel Rosebrock , Alexis A Jourdain, PhD , María Hernández-Sánchez, PhD , Aina Zurita Martinez , Elisa Ten Hacken, PhD , Philip A. Thompson, MBBS , Julian Bryan Iorgulescu, MD PhD , Shuqiang Li, PhD , Matthew S. Davids, MD , Jennifer R. Brown, MD PhD , Ana Lako , Zoe B. Ciantra , Matthew A. Lawlor , William G. Wierda, MD PhD , Anthony G. Letai, MD PhD , Donna S Neuberg, ScD , Christopher J. Ott, PhD , Ignaty Leshchiner, PhD , Vamsi Mootha, MD , Gad Getz, PhD , Catherine J. Wu, MD. MCL-1 and PKA/AMPK Axis Fuel Venetoclax Resistance in Lymphoid Cancers. Blood 134(Supplement 1), 2019.
132. Jeff P. Sharman, MD, Versha Banerji, MD, Laura Maria Fogliatto, MD PhD, Yair Herishanu, MD, Talha Munir, MD, Renata Walewska, George Follows, Karin Karlsson, MD, Paolo Ghia, MD PhD, Gillian Corbett, Patricia Walker, MBBS, Miklos Egyed, Wojciech Jurczak, MD PhD, Gilles Salles, MD PhD, Ann Janssens, Florence Cymbalista, MD PhD, William Wierda, MD,PhD, Steven Coutre, MD, John M. Pagel, MD PhD DSc, Alan Skarbnik, MD, Manali Kamdar, MD, Jennifer Woyach, MD, Raquel Izumi, PhD, Veerendra Munugalavadla, PhD, Priti Patel, MD, Min Hui Wang, PhD, Sofia Wong, John C. Byrd, MD. Prognostic Factors for Progression in Patients (pts) with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) in Complete Molecular Response (CMR) within 3 Months of Therapy with Tyrosine Kinase Inhibitors (TKIs). Blood 134(Supplement 1):1296, 2019.
133. Musa Yilmaz, MD , Hagop M. Kantarjian, MD , Xuemei Wang, MS , Joseph D. Khoury, MD , Farhad Ravandi, MD , Jeffrey L. Jorgensen, MD PhD , Nicholas J. Short, MD , Sanam Loghavi, MD , Jorge E. Cortes, MD , Guillermo Garcia-Manero, MD , Tapan M. Kadia, MD , Koji Sasaki, MD , Marina Y Konopleva, MD PhD , Koichi Takahashi, MD , William G. Wierda, MD PhD , Nitin Jain, MD , Srdan Verstovsek, MD PhD , Zeev E. Estrov, MD , Prithviraj Bose, MD , Sherry A. Pierce, BSN, BA , Rebecca Garris, MSc , Susan M. O'Brien, MD , Elias Jabbour, MD. The Early Achievement of Measurable Residual Disease Negativity in the Treatment of Adults with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia Is a Strong Predictor for Survival. Blood 134(Supplement 1):1297, 2019.
134. Constantine S. Tam, MBBS, MD , Tanya Siddiqi, MD , John N. Allan, MD , Thomas J. Kipps, MD PhD , Ian W. Flinn, MD PhD , Bryone J. Kuss, MBBS, PhD FRACP, FRCPA , Stephen Opat , Paul M. Barr, MD , Alessandra Tedeschi, MD , Ryan Jacobs, MD , Xavier C. Badoux, MBBS, FRACP, FRCPA , Paolo Ghia, MD PhD , Juthamas Sukbuntherng, PhD , Ahmed Hamed Salem, PhD FCP , Kristin Russell, BS , Karl Eckert, BA , Cathy Zhou, MS , Joi Ninomoto, PharmD , Danelle F. James, MD MAS , William G. Wierda, MD PhD. Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study. Blood 134(Supplement 1):35, 2019.
135. Guillaume Richard-Carpentier, MD , Hagop M. Kantarjian, MD , Nicholas J. Short, MD , Farhad Ravandi, MD , Alessandra Ferrajoli, MD , Heather M Schroeder , Guillermo Garcia-Manero, MD , Guillermo Montalban Bravo, MD , Jorge E. Cortes, MD , Monica Kwari, BSN , Christopher Loiselle, BS , Rebecca Garris, MSc , Nicole Volter, RDC , Nitin Jain, MD , Marina Y Konopleva, MD PhD , Koichi Takahashi, MD , Koji Sasaki, MD , William G. Wierda, MD PhD , Elias Jabbour, MD. Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL). Blood 134(Supplement 1):3807, 2019.
136. Patel K, Michot JM, Chanan-Khan AA, Salles GA, Cartron G, Peyrade F, Bouabdallah R , Reid EG, Thomas SK, Wierda WG, Liebowitz D, Pagel JM, Ribrag V, Saville MW, Johnson CM, Ly T, Phillips TJ. ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL). Blood 134(Supplement 1):4079, 2019.
137. Tambaro F, Ragoonanan D, Khazal D, Petropoulos D, Tewari P, Kebriaei P, Wierda WG, Kohorst MA, Mahadeo KM. ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL). Blood 134(Supplement 1):4495, 2019.
138. Furman RR, Wierda WG, Schuh A, Devereux S, Chaves JM, Brown JR, Hillmen P, Martin P, Awan FT, Stephens DM, Ghia P, Barrientos JC, Pagel JM, Woyach J, Burke K, Covey T , Gulrajani M, Hamdy A, Izumi R, Frigault MM, Patel P, Rothbaum W, Wang MH, O'Brien SM, Byrd JC. ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL). Blood 134(Supplement 1):3039, 2019.
139. John N. Allan, MD , Krish Patel, MD , Anthony R. Mato, MDMSCE , William G. Wierda, MD PhD , Javier Pinilla Ibarz, MD PhD , Michael Y. Choi, MD , Susan M. O'Brien, MD , Jeff P. Sharman, MD , Mazyar Shadman, MD , Douglas E Gladstone, MD , Matthew S. Davids, MD , John M. Pagel, MD PhD DSc , Renee Ward, MD PhD , Gary Acton, MD , Pietro Taverna, PhD , Judith A. Fox, PhD , Richard R. Furman, MD , Jennifer R. Brown, MD PhD. Ongoing Results of a Phase 1B/2 Dose-Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible Bruton'S Tyrosine Kinase Inhibitor, Vecabrutinib, in B-Cell Malignancies. Blood 134(Supplement 1):3041, 2019.
140. Abhishek Maiti, MBBS , Hagop M. Kantarjian, MD , Guillermo Garcia-Manero, MD , Marina Y Konopleva, MD PhD , Srdan Verstovsek, MD PhD , Michael Andreeff, MD PhD , Gautam M. Borthakur, MD , Tapan M. Kadia, MD , Naval G. Daver, MD , Naveen Pemmaraju, MD , Courtney D. DiNardo, MDMSc , Sherry A. Pierce, BSN, BA , Lian-Chun Xiao , Xuelin Huang, PhD , William G. Wierda, MD PhD , Steven M. Kornblau, MD , Farhad Ravandi, MD , Jorge E. Cortes, MD. Determinants of Outcomes of FLT3mut Acute Myeloid Leukemia with First Salvage Therapy. Blood 134(Supplement 1):2641, 2019.
141. Vazquez MR , Kantarjian HM, Borthakur GM, O'Brien S, Verstovsek S, Ravandi F, Ferrajoli A, Cortes JE, Kadia TM, |BWierda WG||B, Garcia-Manero G, Dellasala SE, Kehr KA, Pierce SA, Rios MB, Jabbour E. A 20-Year Review of Imatinib in Chronic Phase Chronic Myeloid Leukemia Patients after Failure with Interferon Therapy. Blood 134(Supplement 1):2927, 2019.
142. Uri Rozovski, MD , David M. Harris, PhD , Ping Li, PhD , Zhiming Liu, BS , Taghi Manshouri, PhD , Ivo Veletic, MD , Preetesh Jain, MBBS,MDDM,PhD , Alessandra Ferrajoli, MD , Jan A. Burger, MD PhD , Prithviraj Bose, MD , Philip A. Thompson, MBBS , Nitin Jain, MD , Srdan Verstovsek, MD PhD , William G. Wierda, MD PhD , Michael J Keating, MBBS , Zeev E. Estrov, MD. Constitutively Activated STAT3 Induces the Expression of Gli1 in Chronic Lymphocytic Leukemia Cells. Blood 134(Supplement 1):3018, 2019.
143. Mazyar Shadman, MD MPH , Kavita Sail, PhD , Beenish S Manzoor, PhD , Maryam Sarraf Yazdy, MD , Brian T. Hill, MD , Hande H. Tuncer, MD , John N. Allan, MD , Chaitra S. Ujjani, MD , Nnadozie Emechebe, MPH , Rajesh Kamalakar, MS , Simon Sharmokh, MPH, PharmD , Daniel Dingfeng Jiang, MD PhD , German Pena, MD , Thomas Marshall, PharmD, MS , Jacqueline Nielsen, PhD , Paul M. Barr, MD , Jennifer R. Brown, MD PhD , Anna Schuh, PhD , Toby A. Eyre, MD , Nicole Lamanna, MD , William G. Wierda, MD PhD , Alan Skarbnik, MD , Lindsey E. Roeker, MD , Rajat Bannerji, MD PhD , James M. Pauff, MD PhD , Stephen J. Schuster, MD , George A Follows, MD PhD , Bruce D. Cheson, MD , Barbara F. Eichhorst, MD , Danielle M. Brander, MD , Irina Pivneva, PhD , Annie Guerin, MSc , Anthony R. Mato, MDMSCE. Treatment Discontinuation Patterns for Patients with CLL in the Real-World Settings: Results from a Multi-Center Study. Blood 134(Supplement 1):3048, 2019.
144. Uri Rozovski, MD , David M. Harris, PhD , Ping Li, PhD , Zhiming Liu, BS , Taghi Manshouri, PhD , Ivo Veletic, MD , Preetesh Jain, MBBS,MDDM,PhD , Alessandra Ferrajoli, MD , Jan A. Burger, MD PhD , Prithviraj Bose, MD , Philip A. Thompson, MBBS , Nitin Jain, MD , Srdan Verstovsek, MD PhD , William G. Wierda, MD PhD , Michael J Keating, MBBS , Zeev E. Estrov, MD. Constitutively Activated STAT3 Induces the Production of PTX3 That Contributes to the Induction of Bone Marrow Reticulin Fibrosis in Patient with CLL. Blood 134(Supplement 1):3024, 2019.
145. Kim E, Zhang H, Sivina M, Vaca A, Thompson PA, Jain N, Ferrajoli A, Estrov ZE, Keating MJ, WierdaWG , Rice WG, Andreeff M , Burger JA,. CG-806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broad Signaling Inhibition in Chronic Lymphocytic Leukemia Cells. Blood 134(Supplement 1):3051, 2019.
146. Nicholas J. Short, MD , Hagop M. Kantarjian, MD , Farhad Ravandi, MD , Xuelin Huang, PhD , Naval G. Daver, MD , Courtney D. DiNardo, MD MSc , Marina Y Konopleva, MD PhD , Naveen Pemmaraju, MD , William G. Wierda, MD PhD , Guillermo Garcia-Manero, MD , Koji Sasaki, MD , Jorge E. Cortes, MD , Rebecca Garris, MSc , Marygrace Ward, RDC , Binru Huang, RDC , Corabelle Encarnacion, RDC , Christopher Loiselle, BS , Joseph D. Khoury, MD , Jeffrey L. Jorgensen, MD PhD , Nitin Jain, MD , Joie Alvarez, RN , Nicole Tippett, RN , Susan M. O'Brien, MD , Elias Jabbour, MD. Long-Term Safety and Efficacy of Hyper-CVAD Plus Ponatinib As Frontline Therapy for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Blood 134(Supplement 1):283, 2019.
147. Nitin Jain, MD , Philip A. Thompson, MBBS , Jan A. Burger, MD PhD , Alessandra Ferrajoli, MD , Koichi Takahashi, MD , Zeev E. Estrov, MD , Gautam M. Borthakur, MD , Prithviraj Bose, MD , Tapan M. Kadia, MD , Naveen Pemmaraju, MD , Koji Sasaki, MD , Naveen Garg, MD , Xuemei Wang, MS , Rashmi Kanagal-Shamanna, MD , Keyur Patel, MD PhD , Jeffrey L. Jorgensen, MD PhD , Sa A Wang, MD , Wanda Lopez, RN , Ana Ayala, RN , William Plunkett, PhD , Varsha Gandhi, PhD , Hagop M. Kantarjian, MD , Susan O'Brien, MD , Michael J Keating, MBBS , William G. Wierda, MD PhD. Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of IGHV-Mutated CLL and without Del(17p)/Mutated TP53. Blood 134(Supplement 1):357, 2019.
148. Thompson PA, Keating MJ, Jain N, Ferrajoli A, Kadia TM, Bose P, Wierda WG. Venetoclax Added to Ibrutinib in High-Risk CLL Achieves a High Rate of Undetectable Minimal Residual Disease. [RTS1]. Blood 134(Supplement 1):358, 2019.
149. Nitin Jain, MD , Michael J. Keating, MBBS , Philip A. Thompson, MBBS , Jan A. Burger, MD PhD , Alessandra Ferrajoli, MD , Zeev E. Estrov, MD , Gautam M. Borthakur, MD , Koichi Takahashi, MD , Prithviraj Bose, MD , Nathan H. Fowler, MD , Tapan M. Kadia, MD , Naval G. Daver, MD , Marina Y Konopleva, MD PhD , Yesid Alvarado, MD , Musa Yilmaz, MD , Courtney D. DiNardo, MD MSc , Maro Ohanian, DO , Naveen Pemmaraju, MD , Elias Jabbour, MD , Koji Sasaki, MD , Rashmi Kanagal-Shamanna, MD , Keyur Patel, MD PhD , Jeffrey L. Jorgensen, MD PhD , Sa A Wang, MD , Naveen Garg, MD , Xuemei Wang, MS , Katrina Sondermann, BA , Nichole Cruz, RN , Chongjuan Wei, PhD , Ana Ayala, RN , William Plunkett, PhD , Hagop M. Kantarjian, MD , Varsha Gandhi, PhD , William G. Wierda, MD PhD. Combined Ibrutinib and Venetoclax in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). Blood, 2019.
150. Erin Parry, MD PhD , Camilla K Lemvigh, MSc , Annabelle J Anandappa, MD , Shuqiang Li, PhD , Lillian Werner, MS , Ana Lako , Noelia Purroy, MD PhD , Satyen H Gohil, PhD, M.B.,B.S. , Giacomo Oliveira, PhD , Pavan Bachireddy, MD , Teddy Huang , Ignaty Leshchiner, PhD , Aina Zurita Martinez , Lars Ronn Olsen, PhD , Kenneth Livak, PhD , Gad Getz, PhD , Donna S Neuberg, ScD , Scott J Rodig, MD PhD , William G. Wierda, MD PhD , Peter Kharchenko, PhD , Nitin Jain, MD , Catherine J. Wu, MD. T Cell Determinants of Response and Resistance to PD-1 Blockade in Richter's Transformation. Blood, 2019.
151. Mariela Sivina , Gordon Duncan, MSc , Takashi Sakamoto, MD PhD , Ekaterina Kim, MS , Alicia Vaca, PhD , Elena Maria Hartmann, MD , Michael J Keating, MBBS , Alessandra Ferrajoli, MD , William G. Wierda, MD PhD , Tak Mak, PhD DSc , Andreas Rosenwald, MD , Jan A. Burger, MD PhD. Ibrutinib Therapy Downregulates Toso, the Fcr for IgM, Expression in CLL Patients. Blood, 2019.
152. Giacopelli B , Zhao Q, Ruppert A , Agyeman A , Weigel C, Wu YZ, Gerber M , Rabe KG, Larson MC , Lu J , Blachly JS , Rogers KA, Wierda, WG, Brown JR, Rai KR, Keating M , Rassenti LZ , Kipps TJ, Zenz T , Shanafelt TD , Kay NE , Abruzzo LV , Coombes KR , Woyach JA , Byrd JC , Oakes CC. Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia. Blood 134(8):688-698, 2019.
153. Thompson PA, Srivastava J, Strati P, Jorgensen JL, Breaker J, Hether T, Keating MJ, O'Brien SM, Ferrajoli A, Burger JA, Estrov ZE, Jain N, Wierda WG. Undetectable-Minimal Residual Disease (U-MRD6) (10 -6 sensitivity) Is Associated with Best Progression-Free Survival for Patients Who Achieve Bone Marrow Undetectable MRD4 (10 -4 sensitivity) with First-Line FCR. Blood 132(Supp1):3137, 2018.
154. Wierda WG, Kipps TJ, Durig J, Griskevicius L, Stilgenbauer S, Mayer J, Smolej L, Hess G, Griniute R, Hernandez-Ilizaliturri FJ, Padmanabhan S, Strange M, Nielsen TG, Russell CA.. Ofatumumab Combined with Fludarabine and Cyclophosphamide (O-FC) Shows High Activity in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL): Results From a Randomized, Multicenter, International, Two-Dose, Parallel Group, Phase II Trial. Blood 114(22):90, 2009.
155. Ferrajoli A, O'Brien S, Faderl S, Wierda W, David D, Bang-Ning L, Reuben J, Schlette E, Kantarjian H, Keating M.. Lenalidomide induces complete and partial responses in patients with relapsed and treatment-refractory chronic lymphocytic leukemia (CLL). Blood 108(11):94a, 2006.

Book Chapters

1. Wierda WG, Keating MJ, O'Brien S.. Chronic Lymphocytic Leukemia. In: Cancer: Principles and Practice of Oncology. 8th. Lipppincott Williams & Wilkins: Philadelphia, 2278-2292, 2009.
2. Cortes JE, Kantarjian H., Wierda W. Chronic Leukemias. In: Conn's Current Therapy. W. B. Saunders Company Publications: Pennsylvania, 456-463, 2009.
3. Wierda WG. Gene Therapeutic Approaches for Chronic Lymphocytic Leukemia. In: Unknown, 201-215, 2008.
4. Wierda, WG. Gene Therapy, Vaccines and Immune Modulation. In: Chronic Lymphocytic Leukemia. Informa Healthcare, 2008.